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B I O C H E M I S T R Y
Global ubiquitylation analysis of mitochondria 
in primary neurons identifies endogenous Parkin 
targets following activation of PINK1
Odetta Antico1†, Alban Ordureau2†‡, Michael Stevens1, Francois Singh1, Raja S. Nirujogi1,3, 
Marek Gierlinski4, Erica Barini1§, Mollie L. Rickwood1, Alan Prescott5, Rachel Toth1,  
Ian G. Ganley1, J. Wade Harper2,3*, Miratul M. K. Muqit1,3*
How activation of PINK1 and Parkin leads to elimination of damaged mitochondria by mitophagy is largely based on cell 
lines with few studies in neurons. Here, we have undertaken proteomic analysis of mitochondria from mouse neu-
rons to identify ubiquitylated substrates of endogenous Parkin. Comparative analysis with human iNeuron datasets 
revealed a subset of 49 PINK1 activation–dependent diGLY sites in 22 proteins conserved across mouse and human sys-
tems. We use reconstitution assays to demonstrate direct ubiquitylation by Parkin in vitro. We also identified a subset of 
cytoplasmic proteins recruited to mitochondria that undergo PINK1 and Parkin independent ubiquitylation, indicating 
the presence of alternate ubiquitin E3 ligase pathways that are activated by mitochondrial depolarization in neu-
rons. Last, we have developed an online resource to search for ubiquitin sites and enzymes in mitochondria of neurons, 
MitoNUb. These findings will aid future studies to understand Parkin activation in neuronal subtypes.
INTRODUCTION
Mitochondria perform diverse functions within eukaryotic cells that 
are essential to their survival; however, under physiological condi-
tions, they are exposed to pleiotropic stress including reactive oxygen 
species and misfolded and aggregated proteins that cause mito-
chondrial dysfunction (1, 2). This is particularly relevant in termi-
nally differentiated cell types such as neurons in which aberrant 
mitochondrial homeostasis is linked to diverse neurological syn-
dromes and neurodegenerative disorders (3, 4). Mitochondrial quality 
control pathways have evolved to sense and protect against mito-
toxic stress, of which elimination to lysosomes via the autophagy 
pathway (mitophagy) has been extensively studied in recent years 
(2, 5). Autosomal recessive mutations in human phosphatase and 
tensin homolog (PTEN)–induced kinase 1 (PINK1) and the RING-
In-Between-Ring (IBR)-RING ubiquitin E3 ligase Parkin (encoded by 
PARK6 and PARK2 genes, respectively) are causal for early-onset 
Parkinson’s disease (PD) (6, 7). Landmark cell-based studies have 
demonstrated that these proteins function within a common path-
way to regulate stress-evoked mitophagy via a ubiquitin- dependent 
mechanism (8–10). Upon loss of mitochondrial membrane poten-
tial that can be induced artificially by mitochondrial uncouplers 
[e.g., antimycin A/oligomycin (AO)], PINK1 becomes stabilized and 
activated on the mitochondrial outer membrane (MOM) where it 
phosphorylates both ubiquitin and Parkin at their respective Ser65 
residues, leading to stepwise recruitment and activation of Parkin at 
the MOM (11–15). An analogous pathway is activated upon accumu-
lation of misfolded proteins in the mitochondrial matrix or upon 
mitochondrial damage occurring in cells lacking mitofusin pro-
teins (MFN1 and MFN2), indicative of physiologically relevant 
mitochondrial stress pathways (16, 17). Active Parkin ubiquitylates 
myriad substrates including voltage-dependent anion channels (VDACs), 
MitoNEET/CDGSH iron-sulfur domain-containing protein 1 (CISD1), 
MFNs, hexokinase 1 (HK1), and mitochondrial Rho GTPases (guano-
sine triphosphatases) (MIROs)/RHOTs, leading to its further recruit-
ment and retention at the MOM via a Ser65–phosphorylated ubiquitin 
(phospho-ubiquitin)–dependent feed-forward amplification mech-
anism (15, 18–22). The presence of ubiquitin and/or phospho-ubiquitin 
on damaged mitochondria stimulates recruitment of autophagy 
adaptor receptors of which nuclear domain 10 protein 52 (NDP52), 
optineurin (OPTN), and, to a small extent, Tax1bp1 are required 
for efficient clearance of damaged mitochondria (19, 23, 24).
The initial mechanisms by which Parkin is activated and identi-
fication of bona fide substrates have been mainly studied in human 
cancer lines overexpressing Parkin, and to date, very few studies 
have assessed its molecular function in physiologically relevant 
neuron cell types at the endogenous level. Previous analysis of ubiq-
uitylation in HeLa cells overexpressing Parkin found highest levels 
of ubiquitylation in the abundant VDAC1/2/3 proteins and also re-
vealed moderate ubiquitylation of specific sites within MFN2, 
CISD1, and mitochondrial import receptor subunit TOM20 homolog 
(TOMM20) proteins (19, 20, 25). Ubiquitylation analysis in human 
embryonic stem cell–derived iNeurons (expressing markers of 
excitatory cortical neurons) has revealed endogenous PINK1–
dependent accumulation of phospho-ubiquitin: a 70-, 14-, and 2-fold 
increase in K63, K11, and K6 ubiquitin linkages (the latter being 
lower than that observed in HeLa cells overexpressing Parkin) and 
134 ubiquitylation sites spanning 83 proteins of which the majority 
are localized at the MOM including VDAC1/3 and MFN2 (18, 19). 
Collectively these studies have elaborated a model that suggests that 
PINK1- and Parkin-dependent accumulation of ubiquitin chain types 
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mainly at the MOM is sufficient for downstream signaling and mi-
tochondrial clearance (18, 26).
In previous studies, we have reported that endogenous PINK1 
and Parkin activation can be robustly measured in primary cortical 
neurons derived from mouse embryonic-derived neuronal progen-
itors, that is, an established and widely validated cell system to in-
vestigate neurobiological mechanisms relevant to mature neurons 
(27–29). Here, we have undertaken global di-Glycine (diGLY) 
ubiquitylation analysis in primary cortical neurons of wild-type 
and homozygous PINK1 knockout (KO) mice to map the ubiqui-
tin architecture of mitochondria under normal basal conditions and 
upon activation of PINK1 upon mitochondrial depolarization. After 
5 hours of stimulation, we detect ubiquitylation of 58 mitochondrial 
proteins located mainly within the MOM, associated with an in-
crease in K63 ubiquitin chain linkage type, and a low level of 
mitochondrial protein turnover at this time point that is blocked 
in PINK1 KO neurons. We further demonstrate the regulation of 
mitochondrial substrates by Parkin using cell-based assays in 
Parkin KO neurons and Parkin reconstitution in vitro catalytic activity 
assays. Comparative analysis with human iNeurons datasets elabo-
rated a PINK1/Parkin-dependent ubiquitylation signature on depo-
larized mitochondria in neurons comprising 49 sites across 22 MOM 
proteins conserved between mouse and human neurons that represent 
a cellular readout for PINK1 and Parkin activity and a potential proxy 
readout of PD-linked mitochondrial dysfunction in future studies.
RESULTS
Generation and characterization of wild-type and PINK1 KO 
mouse neurons
To characterize PINK1 and Parkin activity in neurons, we estab-
lished primary cortical neuron cultures from embryonic day 16.5 
(E16.5) mouse embryos at 21 days in vitro (DIV) (Fig. 1A). Immu-
nofluorescence analysis of wild-type mouse DIV21 cultures using 
anti-microtubule associated protein 2 (MAP2) (neuronal marker) 
and anti–glial fibrillary acidic protein (GFAP; glial marker) anti-
bodies confirmed that cultures were highly enriched for neuronal 
cells (~85%) (fig. S1A). We next undertook deep proteomic profil-
ing of wild-type cortical neurons using the histone-based proteomic 
ruler method to estimate the copy number of neuronal markers and 
PD-linked proteins (30). This revealed high copy number of multiple 
neuronal markers including Tubb3 (~11.6 million copies per cell), 
Syp (~1.6 million copies per cell), and Mapt and Eno2 (~1 million 
and 1.1 million copies per cell, respectively) (Fig. 1B). Parkin has 
lower abundance (~18 thousand copies per cell) and ranked at 3672 
on our list of 9431 most abundant proteins, whereas we were un-
able to detect PINK1 peptides under the conditions used (Fig. 1B). 
Of the other PD-linked proteins, from highest to lowest abundance, 
included SNCA (-synuclein) (~4.7 million copies per cell), Parkin-
son disease protein 7 homolog (PARK7/DJ1) (~1.5 million copies 
per cell), Vacuolar protein sorting-associated protein 35 (VPS35) 
(~175 thousand copies per cell), VPS13C and polyamine-transporting 
ATPase 13A2 (ATP13A2) (both 2 thousand copies per cell), and 
Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) 
(~133 copies per cell). Other PINK1 pathway components included 
Ras-related protein Rab-8B (Rab8B) (~4.5 million copies per cell), 
Ras-related protein Rab-8A (Rab8A) (~4.5 million copies per cell), Ras- 
related protein Rab-13 (Rab13) (~1.4 million copies per cell), and 
Ubiquitin carboxyl-terminal hydrolase 30 (USP30) (~7 thousand copies 
per cell) (Fig. 1B and table S1). We also generated quantitative global 
proteomic analysis of cortical neurons that are treated with antimycin A 
(10 M)/ oligomycin (1 M) stimulation for 5 hours [inhibition of 
respiratory chain enzyme complex II/III and adenosine triphosphate 
(ATP) synthase respectively; AO]. We undertook data-independent 
acquisition (DIA) that led to identification and quantification of 
6300 protein groups. We did not detect a substantial portion of the 
proteome being altered by AO at this time point with only three 
proteins significantly increased (Fam216a, Mtm1, and Smarcd2) and 
several decreased including Smyd4, Med29, Ccdc106, and Nktr (fig. 
S1B and table S1). We next undertook high-resolution respirometry 
of DIV21 cultures of wild-type and PINK1 KO neurons under the 
influence of different substrates and inhibitors (fig. S2, A and B). 
Overall, we did not observe any major difference between wild-type 
and PINK1 KO neurons in their utilization of substrates (fig. S2B). 
There was a mild global impairment of mitochondrial respiration in 
PINK1 KO primary compared to wild-type neurons [repeated measure 
analysis of variance (ANOVA), P ≤ 0.05]. In addition, we observed 
a mild decrease in the phosphorylation system control ratio (P/E con-
trol ratio) in PINK1 KO neurons (fig. S2C), suggesting an enhanced 
coupling of oxidation and phosphorylation in PINK1 KO primary 
neurons that may compensate for the reduction in mitochondrial 
respiration and maintain physiological ATP levels.
Biochemical characterization of PINK1-induced ubiquitin 
signaling in mouse neurons
We undertook a time course analysis of PINK1 activation in primary 
mouse neurons following AO stimulation. Endogenous PINK1 levels 
were detectable following immunoprecipitation-immunoblot anal-
ysis, revealing very low expression in neurons under basal conditions 
and increased expression over time upon mitochondrial depolar-
ization (fig. S3A). Immunoblot analysis of Parkin demonstrated basal 
expression that was stable upon mitochondrial depolarization up to 
9 hours (fig. S3A). We optimized the detection of phospho-ubiquitin 
using HALO-multiDSK and immunoblotting with anti–phospho- Ser65 
ubiquitin antibody and signal was abolished using a mutant form 
of HALO-multiDSK (fig. S3B). Furthermore, we did not observe 
any difference in the detection of phospho-ubiquitin using tandem- 
repeated ubiquitin-binding entities (TUBE) pulldowns with HALO- 
multiDSK and HALO-UBAUBQLN1 (fig. S3B). Upon mitochondrial 
depolarization, we observed robust accumulation of phospho-ubiquitin 
at 3 hours, and this was maximal at 5 hours; similarly, we also de-
tected phospho-Parkin upon mitochondrial depolarization (fig. S3A). 
We therefore undertook all subsequent analysis at this time point. 
We next investigated signaling in PINK1 KO neurons and observed 
complete loss of phospho-ubiquitin (Fig. 1C). We have previously 
found that PINK1 activation leads to induction of phosphorylation of a 
subset of Rab GTPases including Rab8A at Ser111 in human cancer 
cell lines (31), and upon mitochondrial depolarization, we observed 
Ser111-phosphorylated Rab8A (phospho-Rab8A) in wild-type neu-
rons, and this was abolished in PINK1 KO neurons (Fig. 1C). Upon 
mitochondrial depolarization of wild-type and Parkin KO neurons, 
we observed loss of phospho-Parkin in Parkin KO neurons and, while 
the level of phospho-ubiquitin was substantially reduced, it was not 
abolished, suggesting that other unknown ubiquitin E3 ligases may 
contribute ubiquitin marks that can be phosphorylated by PINK1 
in mature neurons (fig. S3C), a finding consistent with studies in 
Parkin-deficient iNeurons (19). Furthermore, we observed decreased 
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Fig. 1. PINK1 signaling in mouse cortical neurons. (A) Experimental workflow in primary mouse neurons. E16.5 cortical neurons were cultured for 21 DIV, and membrane 
enrichment was performed after mitochondrial depolarization induced with 10 M antimycin A combined with 1 M oligomycin for 5 hours. DMSO, dimethyl sulfoxide; 
m/z, mass/charge ratio. (B) Copy number: Rank abundance plot depicting the protein copy number abundance of cortical neurons. The x axis denotes copy number 
abundance rank, and the y axis denotes log-transformed copy number intensity. PD-linked genes, neuronal markers, and PINK1-Parkin pathway components are high-
lighted in red, blue, and green colored circles and text, respectively. (C) Immunoblots showing comparative analysis of phospho-Ser65 ubiquitin levels in primary cortical 
neuron cultures from wild-type (WT) and PINK1 KO mice. Cultures were stimulated with antimycin A and oligomycin for 5 hours before membrane enrichment. Phospho-Ser65 
ubiquitin was detected by immunoblotting after ubiquitin enrichment by incubating with ubiquitin- binding resin derived from Halo-multiDSK (mDSK). Affinity captured 
lysates were also subjected to immunoblotting with total ubiquitin antibody. Immunoprecipitation (IP) showed PINK1 protein stabilization after mitochondrial depolar-
ization. Phospho-Ser111 Rab8A and phospho-Ser65 Parkin were detected by immunoblotting. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Lysates were also 
subjected to immunoblotting with indicated antibodies for loading and protein expression controls. IB, immunoblot. (D and E) C57BL/6J mouse cortical neurons (DIV 21) 
were depolarized with AO for 5 hours, and whole-cell lysates were subjected to Pt-PRM (parallel reaction monitoring) quantification. Abundance (fmol) for individual 
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observations in human Parkin S65A iNeurons (19) and human Par-
kin S65N patient–derived fibroblasts (29), suggesting a potential 
feedback mechanism of Parkin activation on PINK1 stabilization. 
We have previously observed that PINK1-induced phospho-Rab8A 
can occur in HeLa cells that lack Parkin or in Parkin KO mouse 
embryonic fibroblasts (MEFs), and consistent with this, we did 
not observe any difference in phospho-Rab8A in wild-type or Parkin 
KO neurons following mitochondrial depolarization (fig. S3C). It 
has been reported that additional monogenic forms of Parkinson’s 
may interplay with the PINK1/Parkin pathway including the As-
p620Asn (D620N) mutation of the retromer-associated VPS35 gene 
(32, 33). However, we did not observe any alteration in phospho- 
ubiquitin or phospho-Rab8A in VPS35 D620N homozygous and 
heterozygous neurons compared to wild-type controls following 
mitochondrial depolarization (fig. S4).
We next used targeted parallel reaction monitoring (PRM) pro-
teomic analysis in whole-cell lysates of mature DIV21 neurons to 
quantitatively assess ubiquitin changes upon AO stimulation and 
observed an approximate 52-fold increase in phospho-ubiquitin with 
a stoichiometry of ubiquitin phosphorylation of ~0.13 at 5-hour 
treatment (Fig. 1D). Under basal conditions, we detected nearly all 
ubiquitin chain linkage types including K6, K11, K27, K33, K48, and 
K63, and upon 5 hours of AO treatment, we only observed an in-
crease in K63 chain linkages (Fig. 1E). In parallel studies, we under-
took PRM analysis of less mature DIV12 neurons in which Parkin 
expression is lower (28) and stimulated these cells with AO for less 
time at 3 hours. In TUBE pulldowns of whole-cell lysates or mito-
chondrial-enriched fractions, we observed an approximate 300-fold 
and 40-fold increase in phospho-ubiquitin, respectively, that was not 
associated with any significant increase in ubiquitin chain linkage 
types (fig. S5). This suggests that basal mitochondrial ubiquitin levels in 
neurons may be sufficient to promote the initial generation of phospho- 
ubiquitin under conditions where Parkin activity is not maximal.
Quantitative proteome and diGLY proteome 
of mitochondria in mouse cortical neurons under basal 
conditions and mitochondrial depolarization
We next used a tandem mass tagging (TMT)–MS3–based pipeline 
(25) (Fig. 2A) to quantify the mitochondrial proteome abundance 
and the mitochondrial ubiquitylome under basal conditions and upon 
mitochondrial depolarization that has been previously deployed in 
human iNeurons (18). We isolated mitochondria-containing mem-
brane fractions from quintuplicate cultures of DIV21 C57BL/6J 
mouse primary cortical neurons that were untreated or treated with 
10 M antimycin A and 1 M oligomycin (AO) for 5 hours (fig. S6, 
A and B). We observed few changes in the proteome abundance 
following mitochondrial depolarization; of the 6255 proteins quan-
tified (table S2), 4 proteins [Calsyntenin-2 (CLSTN2), Synaptotagmin-5 
(SYT5), Myocardin-related transcription factor A (MKL1), and 
Histone H2B type 3-A (HIST3H2BA)] were significantly reduced and 
1 protein [Protein phosphatase 1H (PPM1H)] significantly increased 
after AO treatment (fig. S6C). There was a slight shift to the left in 
the AO proteome compared to the untreated proteome, suggesting 
a low level of turnover (fig. S6C). This is consistent with analysis 
undertaken in iNeurons stimulated with AO (18).
We next determined the mitochondrial ubiquitylome in mouse 
neurons using diGLY affinity capture coupled with quantitative 
proteomics (Fig. 2A and fig. S6, A and B). Tryptic peptides from 
membrane-enriched extracts of mouse primary cortical neurons 
untreated or treated with AO for 5 hours were subjected to -diGLY 
immunoprecipitation, and samples were analyzed using 11-plex TMT- 
MS3 with diGLY peptide intensities normalized with total protein 
abundance measured in parallel (Fig. 2A and table S2; see Materials 
and Methods). We detected and quantified ~9154 diGLY-containing 
Kgg peptides, of which 5616 are unique sites. Of those unique sites, 
559 are statistically up-regulated (normalized for total proteome) 
upon AO treatment (Fig. 2A). We next analyzed the data for the 
number of ubiquitylated mitochondrial proteins using the recently 
published MitoCarta 3.0 database containing data on 1140 mouse 
gene encoding proteins that are strongly localized to mitochondria 
including their submitochondrial location (34). Three hundred forty- 
five unique diGLY-containing Kgg peptides were detected in a total 
of 139 mitochondrial proteins under basal and induced conditions, 
of which 54 proteins were located in the MOM, 42 proteins were 
located in the mitochondrial inner membrane (MIM), 19 proteins 
were located in the matrix, 10 proteins are of unknown mitochon-
drial sublocation, 9 proteins are membrane associated, and 5 pro-
teins are in the intermembranous space (IMS) (Fig. 2, B and C). The 
major portion of ubiquitylated proteins up-regulated by AO were MOM 
localized, accounting for 16.6% (MitoCarta, 21.3%) after 5 hours 
of mitochondrial depolarization (Fig. 2, B and C). We also detected 
Kgg peptides of several mitochondrial membrane proteins, Tudor 
and KH domain-containing protein (TDRKH), ATP-binding cas-
sette sub-family D member 3 (ABCD3), Dephospho-CoA kinase 
domain-containing protein (DCAKD), and Dehydrogenase/reductase 
SDR family member 7B (DHRS7B); MIM proteins Retinol dehydroge-
nase 13 (RDH13) and CDP-diacylglycerol--glycerol-3-phosphate 
3-phosphatidyltransferase (PGS1); and matrix proteins Glutamate 
dehydrogenase 1 (GLUD1) and 39S ribosomal protein L22 (MRPL22) 
that were increased about twofold or more following AO (table S2). 
On the basis of MS1-abundance information and TMT quantifica-
tion, we performed a simple ranking analysis of Kgg peptides 
cross-referenced to MitoCarta 3.0 (fig. S7A) to determine the most 
abundant MOM ubiquitylation sites, and these included Carnitine 
O-palmitoyltransferase 1 (CPT1) (K180, K195, and K508), Cyto-
chrome b5 type B (CYB5B) (K30), Voltage-dependent anion-selective 
channel protein 1 (VDAC1) (K122 and K187), HK1 (K819, K243, and 
K247), CISD1 (K68 and K79), NADH-cytochrome b5 reductase 3 
(CYB5R3) (K115 and K120), and Mitochondrial import receptor 
subunit TOM70 (TOMM70) (K171 and K240) (fig. S7A). Con-
versely, we also performed similar analysis on MOM ubiquitylation 
sites that are most reduced following AO treat ment (fig. S7B). This 
revealed down-regulated sites for PARK7/DJ1 (K93), VDAC1 (K33), 
phoshoglycerate mutase 5 (PGAM5) (K73, K140, K161), and 
TOMM20 (K56, K61) (fig. S7B). Comparison of the basal ubiquitin 
levels of the most up-regulated and down-regulated MOM sites did 
not generally predict their subsequent modification following 
AO treatment; for example HK1, CYB5R3, and TOMM70 exhibited 
basal ubiquitin at sites in the range of 1.5 × 106 but became highly 
modified (fig. S7, A and B).
Overall, 160 Kgg peptides from 70 mitochondrial proteins were 
significantly elevated by AO treatment (Fig. 2, B and D) and this 
compared to 112 Kgg peptides from 56 mitochondrial proteins that 
were significantly elevated by AO treatment in human iNeurons (18). 
Consistent with previous analysis in human iNeurons, we found 
that the majority of proteins were MOM localized (Fig. 2, B and C), 
and 51 ubiquitylation sites spanning 23 mitochondrial proteins were 
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Fig. 2. Global ubiquitylation analysis of mitochondria in neurons upon mitochondrial depolarization. (A) C57BL/6J primary cortical neurons were depolarized with 
AO (5 hours), and membrane-enriched lysates were subjected to diGLY capture proteomics. Fold increase for individual ubiquitylated targets is shown in the volcano plot. 
The x axis specifies the fold changes, and the y axis specifies the negative logarithm to the base 10 of the t test P values. Dots (1606) reflect the significant hits [Welch’s 
t test (S0 = 2), corrected for multiple comparison by permutation-based false discovery rate (FDR; 1%)]. Five hundred fifty-nine and 1047 dots represent ubiquitylated 
targets up-regulated or down-regulated after mitochondrial depolarization, respectively. diGLY peptide of proteins associated with mitochondria (MitoCarta 3.0) or MOM 
localization are indicated. (B) Schematic showing sites of ubiquitylation in mouse cortical neurons according to MitoCarta 3.0. Residue numbers for diGLY-modified Lys 
residues are shown. (C) Distribution of changes in diGLY peptides for proteins that localize in the mitochondrial subcompartments: matrix, MIM, MOM, IMS, membrane, 
and unknown (MitoCarta 3.0). (D) Venn diagram of overlapping diGLY sites observed in site observed for mitochondrial enriched mouse cortical neurons (5 hours after 
depolarization) and sites observed from mitochondrial enriched human iNeurons (3 or 4 hours after depolarization) (18). All peptides used were increased by at least 
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acyl–coenzyme A synthetase long chain 1 (ACSL1), 1-acyl-sn-glycerol-3-
phosphate acyltransferase epsilon (AGPAT5), Outer mitochondrial 
transmembrane helix translocase (ATAD1), CISD1, CPT1, CYB5R3, 
Peroxiredoxin-like 2A (FAM213A), Mitochondrial fission 1 protein 
(FIS1), FKBP8 (FK506 binding protein 8), Ganglioside-induced 
differentiation-associated protein 1 (GDAP1), Growth hormone- 
inducible transmembrane protein (GHITM), HK1, MFN1/2, RAB24, 
RHOT1/2, Synaptojanin-2-binding protein (SYNJ2BP), TDRKH, 
TOMM70, and VDAC1/2/3 (Fig. 2, B and D). In addition, we iden-
tified two proteins whose ubiquitylation was increased in both 
mouse neurons and human iNeurons, although the sites were dis-
tinct, namely, the mitophagy receptor BCL2/adenovirus E1B 19 kDa 
protein-interacting protein 3-like (BNIP3L), DCAKD (Fig.  2D). 
Of mitochondrial substrates specific to mouse neurons, we interest-
ingly detected ubiquitylation of enzymes linked to dopamine and 
catecholamine metabolism including monoamine oxidase A 
(MAO-A), MAO-B, and catechol-O-methyltransferase (COMT), 
which degrade dopamine and are established drug targets for symp-
tomatic treatment of PD (table S2). Previous diGLY analysis found 
that MAOB was ubiquitylated in response to mitochondrial depo-
larization in HeLa, HCT116, and SH-SY5Y cells (20). COMT is 
expressed in iNeurons, but there was no increase in ubiquitylation, 
while MAO-A and MAO-B were not expressed (18).
Previous TMT analysis of HeLa cells (overexpressing Parkin) 
has indicated that activation of PINK1 and Parkin may stimulate 
recruitment of a large panoply of proteins to depolarized/damaged 
mitochondria, as determined by the detection of 137 ubiquitylation 
sites derived from 85 cytosolic proteins including Parkin and auto-
phagy receptors such as OPTN and Tax1-binding protein 1 ho-
molog (TAX1BP1) in mitochondrial- enriched fractions (25). Under 
endogenous conditions, we were unable to detect ubiquitylation sites 
for Parkin or autophagy receptors in our analysis but could detect 
unmodified peptides for OPTN and TAX1BP1 (table S2). Compara-
tive analysis of datasets revealed approximately 80 cytosolic proteins 
whose ubiquitylation was increased upon AO treatment in both 
mouse neuron and HeLa cell analyses, and in a significant number 
of proteins, the site of ubiquitylation was identical between datasets 
(table S3). These common sites included the p97 ubiquitin-binding 
cofactor FAS-associated factor 2 (FAF2) (K167), the amyotrophic 
lateral sclerosis (ALS)–linked protein TAR DNA-binding protein 43 
(TDP-43) (K181), the protein kinase AKT1 (K426), and Small 
ubiquitin-related modifier (SUMO) E3 ligase, Transcription inter-
mediary factor 1-beta (TRIM28) (K320) (table S3 and fig. S7C) (25). 
In neurons, we also found a large number of ubiquitylation sites in 
cytosolic kinases that were up-regulated upon AO treatment includ-
ing glycogen synthase kinase 3, calcium/calmodulin-dependent 
protein kinase 2// (CAMK2//), several protein kinase C 
(PRKC) isoforms, Unc-51 like autophagy activating kinase 1 (ULK1) 
(K162), and LRRK2 (K1132) (table S4 and fig. S7C). Recent studies have 
indicated a role for ULK1 in the initiation of mitophagy (35, 36), 
and LRRK2 has also been shown to regulate basal mitophagy (37); in 
future work, it will be interesting to determine whether other cytoso-
lic kinase and phosphatase signaling components identified in our 
screen may be implicated in mitophagy mechanisms (table S4).
Quantitative diGLY proteome analysis in mitochondria 
of wild-type and PINK1 KO mouse cortical neurons
We next determined which ubiquitylated substrates were depen-
dent on activation of PINK1 (fig. S8A). We isolated mitochondria 
from cultures of primary cortical neurons from crosses of wild-type 
and PINK1 KO mice that were untreated or treated with AO for 
5 hours (fig. S8, A and B). We compared the proteome of triplicate 
cultures of wild-type and PINK1 KO mouse cortical neurons that 
were untreated or treated with AO for 5 hours. Similar to the previ-
ous experiment, we found very little change in the proteome abun-
dance of wild-type neurons and the total proteome was slightly 
reduced in wild-type neurons following AO treatment, indicating 
increased turnover (Fig. 3A and fig. S8C). This mild reduction was 
completely blocked in the PINK1 KO neurons (Fig. 3A and fig. 
S8C). These results are consistent with similar observation of the 
proteome of wild-type and Parkin S65A iNeurons following AO 
treatment for 6 hours (18). Furthermore, quantitative TMT analysis 
demonstrated a ~50-fold increase in Ser65–phospho-ubiquitin upon 
AO in wild-type neurons that was abolished in PINK1 KO neurons 
(Fig. 3B). In parallel, we also measured Ser57–phospho-ubiquitin 
that is independent of AO treatment, and there was no difference 
between wild-type and PINK1 KO neurons (Fig. 3B).
We next determined the mitochondrial ubiquitylome in mouse 
neurons using diGLY affinity capture coupled with quantitative 
proteomics (fig. S6, A and B) (18). Tryptic peptides from mitochon-
drial enriched extracts of primary cortical neurons of wild-type and 
PINK1 KO mice with or without mitochondrial depolarization (5 hours) 
were subjected to -diGLY immunoprecipitation, and samples were 
analyzed using 11-plex TMT-MS3 (wild type: three untreated/three 
AO; KO: three untreated/two AO) with diGLY peptide intensities 
normalized with total protein abundance measured in parallel 
(Fig. 3, C and D, and fig. S8, A and B) (see Materials and Methods).
We quantified a total of ~7210 diGLY-containing Kgg peptides 
of which ~3951 are unique sites (Fig. 3C). From these, we identified 
177 ubiquitylation sites in 99 proteins in wild-type neurons after 
5 hours of AO stimulation, whose abundance was significantly in-
creased (Fig. 3C), and the majority of sites had been detected in 
AO-treated C57BL/6J neurons (Fig. 2). AO treatment of PINK1 KO 
mouse neurons for 5 hours led to substantially reduced AO-induced 
ubiquitylation of mitochondrial proteins including all but one of 
the common set of 23 MOM proteins (FKBP8) identified previously 
(Fig. 3D and fig. S6D). In contrast, we observed ubiquitylation of a 
number of cytosolic proteins including CAMK2// and Sorting 
nexin-3 (SNX3) whose ubiquitylation was independent of PINK1 
(Fig. 3D and fig. S8D). Principal components analysis revealed that 
the 5-hour depolarization data of wild type were not similar to the 
untreated wild-type and/or PINK1 KO samples, which were also 
more similar to each other (fig. S8E).
Validation of Parkin-dependent substrates using cell-based 
and in vitro studies
Based on the ranking of the most abundant ubiquitylated (Kgg) 
mitochondrial sites (Fig. 2, A and B, and fig. S7A), we proceeded to 
investigate whether we could detect endogenous substrate ubiqui-
tylation via biochemical analysis in wild-type C57BL/6J neurons 
that were either untreated or stimulated with AO for 5 hours. Mito-
chondrial-enriched fractions from neurons were subjected to TUBE 
pulldowns with HALO-UBAUBQLN1 or HALO-multiDSK (and non-
binding multiDSK mutant) and immunoblotted with specific an-
tibodies for each substrate and phospho-ubiquitin to confirm 
Parkin activation (fig. S9). This confirmed previous observations 
(28, 29) that CISD1 can undergo multi-monoubiquitylation upon 
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HALO-multiDSK pulldowns. We also observed robust monoubiq-
uitylation of CPT1, an integral outer membrane protein that con-
verts activated fatty acids into acylcarnitines and facilitates their 
transport into mitochondria (fig. S9) (38). This was more easily 
detected with HALO-multiDSK pulldown, and we used HALO- 
multiDSK to undertake a time course analysis and confirmed that 
CPT1 undergoes time-dependent ubiquitylation similar to CISD1 
following AO treatment (Fig. 4A). We observed a high–molecular 
weight species of ~140 kDa that was immunoreactive to the CPT1 
antibody following HALO-multiDSK pulldown (Fig. 4 and figs. S9 
and S10A). This was present under basal conditions but increased 
after AO treatment. CPT1 is reported to form complexes at the 
MOM and oligomerize (39), and we cannot rule out that the upper 
band represents oligomerized species of ubiquitylated CPT1.
We next assessed CPT1 ubiquitylation alongside CISD1 in trip-
























































Log2 5-hour AO (PINK1
–/–/PINK1+/+)












































































PINK1+/+ Log2  (5-hour AO/UT)PINK1
–/–
Fig. 3. Global ubiquitylation analysis of mitochondria in neurons of PINK1 wild-type and KO neurons. (A) Total protein abundance of membrane-enriched lysates 
in PINK1+/+ or PINK1−/− neurons. Fold increase for individual protein is shown in the volcano plot. The x axis specifies the fold changes, and the y axis specifies the negative 
logarithm to the base 10 of the t test P values [Welch’s t test (S0 = 0.585), corrected for multiple comparison by permutation-based FDR (5%)]. Proteins associated 
with mitochondria (MitoCarta 3.0) or MOM are indicated. (B) Abundance for phospho-Ser65 (top) or phospho-Ser57 (bottom) of ubiquitin (Ub) was quantified and plotted 
as fold change to untreated wild-type samples. Error bars represent SEMs (n = 3). Error bars represent SEMs (n = 3, 3, 3, and 2). (C and D) The same as (A) but diGLY- 
containing peptides derived from (C) PINK1+/+ or (D) PINK1−/− cells. (C) One hundred eighty-seven and 11 sites or (D) 26 and 0 sites, respectively, represent statistically 
significant ubiquitylated targets up-regulated or down-regulated after mitochondrial depolarization. [Welch’s t test (S0 = 1), corrected for multiple comparison 
by permutation-based FDR (1%)]. diGLY peptides associated with mitochondria (MitoCarta 3.0) or MOM are indicated. Square-shaped dots indicate diGLY peptides not 
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neurons (fig. S10A) with their respective wild-type littermate con-
trols. Mitochondrial fractions from neurons untreated or stimu-
lated with AO for 5 hours were subjected to TUBE pulldowns with 
HALO-multiDSK, demonstrating that CPT1 monoubiquitylation 
was abolished in Parkin and PINK1 KO neurons and this paralleled 
loss of CISD1 ubiquitylation (Fig. 4B and fig. S10A). Furthermore, the 
increased ubiquitylation of the ~140-kDa CPT1-immunoreactive 
species was also attenuated in PINK1 and Parkin KO neurons. We 
also explored whether CPT1 ubiquitylation can independently be 
detected in a different cell system and analyzed human SH-SY5Y 
neuroblastoma cell lines that express endogenous PINK1 and Parkin (fig. 
S10B). Upon addition of AO, we observed time-dependent accumu-
lation of CPT1 ubiquitylation that was maximal at 9 hours as-
sociated with an increase in endogenous phospho-Parkin (fig. S10B). 
From 9 to 24 hours, the levels of total Parkin and phospho-Parkin 
significantly reduced, and this was accompanied by a decrease in 
CPT1 ubiquitylation, consistent with its Parkin dependence (fig. 
S10B). The detection of AO-induced ubiquitylation of other mito-
chondrial proteins varied depending on the ubiquitin-affinity 
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Fig. 4. Validation of Parkin-dependent substrates in cell-based studies. (A) Time course analysis of CPT1 and CISD1 ubiquitylation following AO stimulation 
in C57BL/6J cortical neurons. Halo-multiDSK (mDSK) pulldown immunoprecipitated and inputs were subjected to immunoblot with anti-CPT1, anti-CISD1, anti– 
phospho-Ser65 ubiquitin, and anti-ubiquitin antibodies. Asterisk (*) indicates high molecular weight CPT1 reactive species. (B) CPT1 and CISD1 ubiquitylation is abro-
gated in Parkin KO neurons. Membrane lysates of Parkin wild-type and KO cortical neurons after 5 hours of AO stimulation were subjected to ubiquitylated-protein capture 
by Halo-multiDSK (mDSK), before immunoblot with anti-CPT1, anti-CISD1, anti–phospho-Ser65 ubiquitin and anti-ubiquitin antibodies. Relative inputs are shown at the 
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detected via HALO-UBAUBQLN1 pulldown (fig. S9). There were also 
several mitochondrial proteins exhibiting substantial basal ubiquityl-
ation including AGPAT5, MFN2, and TOMM70 that prevented un-
ambiguous detection of enhanced ubiquitylation upon AO 
treatment by our TUBE-based assay (fig. S9).
The stoichiometry of ubiquitylation of these substrates may also 
be at levels below the sensitivity of detection of this assay. To ad-
dress this, purified mitochondrial extracts from wild-type or PINK1 
KO MEFs (that express near-undetectable levels of endogenous 
Parkin) treated with or without AO were incubated together with or 
without recombinant human Parkin in vitro with a reaction mix con-
taining E1 ubiquitin-activating ligase, UbcH7 conjugating E2 ligase, 
ubiquitin, and Mg-ATP. After 120 min, reactions were terminated 
with SDS sample buffer in the presence of 2-mercaptoethanol and 
heated at 100°C, and substrate ubiquitylation was assessed by im-














































































Fig. 5. Validation of Parkin-dependent substrates in in vitro studies. (A) MEF PINK1 wild-type and KO were depolarized with AO for 4 hours; mitochondria were iso-
lated and incubated with recombinant Parkin for in vitro ubiquitylation assay against endogenous mitochondrial substrates. Ubiquitylated proteins were detected with 
the indicated antibodies. (B and C) Parkin ubiquitylates CPT1 in vitro. (B) Recombinant CPT1 protein was assessed for ubiquitylation assay by Parkin with full-length 
PINK1 (WT), Kinase-inactive (KI), and water (-) as negative control. Miro1 recombinant protein was used as positive control. (C) Time course for CPT1 showed ubiquitylation 
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CYB5B, HK1, MFN2, and total VDAC (Fig. 5A). In the absence of 
AO treatment, PINK1 and Parkin were inactive in the assay with no 
evidence of phospho-ubiquitin or substrate ubiquitylation, respec-
tively (Fig. 5A). In AO-stimulated mitochondria, addition of Parkin 
led to multi-monoubiquitylation of CISD1 and a smear of CPT1 
ubiquitylation, consistent with the TUBE pulldown assays (Fig. 5A). 
Under these assay conditions, we were also able to observe robust 
monoubiquitylation of CYB5B, HK1, MFN2, and VDAC accompanied 
by substantial high molecular–weight phospho-ubiquitin signal 
(Fig. 5A). These signals were abolished in PINK1 KO cells, consistent 
with PINK1-dependent activation of Parkin in the assay (Fig. 5A). 
We observed that in AO-stimulated mitochondria without Parkin, 
ubiquitin was predominantly phosphorylated as mono-ubiquitin, 
indicating that PINK1 may initially target free mono-ubiquitin at the 
mitochondria before Parkin-catalyzed ubiquitin of substrates and 
chains that is consistent with our PRM analysis of DIV12 neurons 
where Parkin is expressed at low levels (fig. S5). To confirm that 
these results were also relevant to human mitochondria, we under-
took similar analysis of HeLa cells (that express no Parkin) incubated 
with or without recombinant Parkin and again observed robust 
ubiquitylation of CISD1, CPT1, CYB5B, HK1, MFN2, and VDACs 
only in AO-stimulated mitochondria incubated with Parkin and 
not in dimethyl sulfoxide (DMSO)–stimulated mitochondria with 
Parkin (fig. S11).
We have previously reported an entirely in vitro reconstitution 
assay of Parkin E3 ligase activity that monitors multi-monoubiqui-
tylation of RHOT1/Miro1 (residues 1 to 592) and the formation of 
free poly-ubiquitin chains (40). To assess whether Parkin (activated 
by phosphorylation of PINK1) directly ubiquitylates CPT1, we 
phosphorylated untagged full-length Parkin with the active insect 
ortholog of PINK1, Tribolium castaneum (TcPINK1), in the presence 
of ATP and then added a reaction mix containing E1 ubiquitin- 
activating ligase, UbcH7 conjugating E2 ligase, ubiquitin, Mg-ATP, 
and a fragment of CPT1 (residues 145 to 773) alongside glutathione 
S-transferase (GST)–Miro1 (residues 1 to 592) that were expressed 
and purified in Escherichia coli (fig. S12). After 30 min, reactions were 
terminated with SDS sample buffer in the presence of 2-mercaptoethanol 
and heated at 100°C; substrate ubiquitylation was assessed by immuno-
blot analysis with antibodies that detect ubiquitin (FLAG), CPT1, 
and Miro1. Consistent with previous findings in the absence of 
PINK1 phosphorylation, Parkin was inactive, as no evidence of free 
ubiquitin chain formation or Miro1 ubiquitylation was observed; with 
the addition of wild-type TcPINK1, Miro1 multi-monoubiquitylation 
in addition to free polyubiquitin chain formation was observed (Fig. 5B). 
No significant Miro1 ubiquitylation or polyubiquitin chain forma-
tion was observed in the presence of the kinase-inactive TcPINK1 
(D359A) (Fig. 5B). Under these conditions, we observed multi- 
monoubiquitylation of CPT1, indicating that this is also a direct 
substrate of Parkin. To determine the temporal dynamics of CPT1 
ubiquitylation, we undertook a time course analysis and observed 
the appearance of multi-monoubiquitylation at 10  min following 
addition of activated Parkin, and this increased in a time-dependent 
manner and paralleled polyubiquitin chain formation (Fig. 5C). We 
also tested additional mitochondrial substrates identified from our 
diGLY mass spectrometry (MS) screen including FAM213A, MAO-A, 
MAO-B, and ACSL1 (residues 46 to end) that forms a complex with 
CPT1 (and VDAC) to promote influx of activated fatty acids into 
the mitochondria (Fig. 2D and fig. S12) (38). All underwent mono- 
ubiquitylation following addition of PINK1-activated Parkin, further 
suggesting that Parkin preferentially catalyzes mono/multi- 
monoubiquitylation of substrates in vitro (fig. S13).
We next investigated whether nonmitochondrial proteins whose 
ubiquitylation was increased following AO treatment are direct Parkin 
substrates (Figs.2A and 3D and fig. S14A). Under similar conditions 
described above, we incubated SNX3, CAMK2, and CAMK2 with 
activated Parkin in vitro [fig. S14, B to D (left)]. We observed free 
polyubiquitin chain formation but no significant substrate phos-
phorylation, indicating that these are not Parkin substrates and un-
likely to be regulated by active Parkin in neurons. MS data did not reveal 
any difference in sites of ubiquitylation in these proteins between 
wild-type and PINK1 KO neurons following stimulation with AO, 
suggesting that additional ubiquitin E3 ligases may be activated and 
recruited to the mitochondria upon AO treatment in a PINK1- 
independent manner [Fig. 3D and fig. S14, B to D (right)].
DISCUSSION
Our groups have previously demonstrated the utility of primary 
mouse neurons and human iNeurons to study endogenous Parkin 
activation including conservation of Parkin activation by PINK1- 
dependent phosphorylation of Ser65 (18, 19, 29). Combining a diGLY/ 
TMT-MS3 workflow (25) in mouse neurons with comparative data 
from previous analysis in human iNeurons (18) has elaborated a de-
fined set of endogenous substrates of Parkin conserved in mouse and 
human neuron cell types (Fig. 2). Notably, from many thousands of 
peptides detected by MS in the screen, we found 49 unique diGLY 
sites in 22 proteins in which ubiquitylation was increased greater 
than twofold or more in neurons upon activation of PINK1 by 
mitochondrial depolarization (Figs. 2 and 3). We also identified two 
proteins, BNIP3L and DCAKD, whose ubiquitylation was increased 
in both mouse and human iNeurons albeit at different sites (Fig. 2). 
Furthermore, all of the sites were present on proteins localized at the 
MOM, consistent with previous studies on how activation of PINK1 
and Parkin on the MOM is sufficient to induce clearance of damaged 
mitochondria via mitophagy (8–10). This was associated with the 
enhanced formation of phospho-ubiquitin and K63 chain linkages in 
mouse neuronal mitochondria (Fig. 1, D and E), which was also found 
to be increased 70-fold in human iNeurons upon mitochondrial 
depolarization (18).
Of the common substrates identified in our neuronal systems, a 
number have been previously quantified in HeLa and human iNeurons 
including CISD1, HK1, MFN1/2, RHOT1/2, TOMM70, and VDAC1/ 
2/3, and their collective ubiquitylation together with other substrates 
has been associated with mitophagic signaling and clearance (18, 19). 
Our analysis also found ATAD1 (Msp1) to be ubiquitylated upon 
Parkin activation (Fig. 2). Akin to p97/Cdc48, Msp1 extracts mis-
folded proteins from the MOM, providing a direct link between 
a Parkin substrate and mitochondrial quality control component 
(41, 42). We identified common ubiquitylation sites on FKBP8 (also 
known as FKBP38) and SYNJ2BP (also known as OMP25) that are 
both anchored to the MOM via translocase of outer mitochondrial 
Membrane (TOM)–independent “tail anchor” mitochondrial target-
ing signals within a C-terminal juxtamembrane sequence known as 
the CSS (43). The CSS of FKBP38 has also been demonstrated in 
MEFs to mediate its escape from the mitochondria to the endoplasmic 
reticulum (ER) during mitophagy, thereby avoiding its degrada-
tion, and this was also dependent on Parkin activity (44). However, 
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PINK1, suggesting that an alternate ubiquitin E3 ligase targets this 
protein, and in future studies, it will be interesting to assess whether 
FKBP8 undergoes escape to the ER in neurons and dissect the mech-
anism. Activation of Parkin in neurons may also be associated with 
proximal signaling events independent of mitophagy, and several of 
the common neuronal sites that we identified occur on proteins in-
volved in fatty acid oxidation and metabolism in the mitochondria 
including CPT1, ACSL1, VDACs, and CYB5R3 (Figs. 2 and 3). 
Recently, several in vivo physiological studies have suggested a link 
between fatty acid oxidation and mitophagy mechanisms in non- 
neuronal tissues (45, 46), and in future work, it will be interesting to 
investigate whether Parkin-induced ubiquitylation of these proteins 
affects fatty acid metabolism at the molecular level in neurons.
Since this is the first study to define common substrates regulated 
by human and mouse Parkin, we undertook a multiple sequence align-
ment analysis of the human Lys-targeted sequences to identify a putative 
recognition motif for Parkin; however, this did not reveal a clear targeting 
sequence for Parkin-directed lysine ubiquitylation (fig. S15), consistent 
with previous studies that have suggested that Parkin lacks sequence 
and structural specificity for substrate ubiquitylation (18–20, 29).
Previous analysis of VDAC1 has suggested that the topology of 
the protein at the MOM and surface exposure of Lys residues to the 
cytosolic side strongly influence Parkin targeting; however, it is not 
known if this is a general mechanism (18, 19). Structural analysis to 
date has elaborated the mechanism of Parkin activation by PINK1 
phosphorylation of Parkin and ubiquitin (47, 48), and in future studies, 
it will be interesting to reconstitute Parkin-catalyzed ubiquitylation 
of model substrates and solve structures of Parkin bound to E2 
and substrate to uncover any autonomous structural determinants 
of lysine recognition by Parkin, and our elaboration of its key sub-
strates in neurons will aid in these studies.
The ubiquitylation of MOM proteins on damaged mitochondria 
is followed by the recruitment of the autophagy receptor proteins 
NDP52, p62, OPTN, Tax1bp, and Next to BRCA1 gene 1 protein 
(NBR1), and several studies suggests that NDP52 and OPTN are the 
main ubiquitin-dependent receptors for efficient mitophagic clear-
ance of damaged mitochondria both in HeLa cells and neurons 
(23, 24, 49). The mechanism of how these are recruited to the MOM 
is not fully understood since NDP52 and OPTN have been demon-
strated to bind diverse ubiquitin chain types including M1, K48, and 
K63 chains (50, 51), and there are conflicting reports on how re-
cruitment of these receptors is affected by phospho-ubiquitin 
(19,  23,  50,  52). The Ub-binding domain in ABIN proteins and 
NEMO (UBAN) domain of OPTN preferentially binds M1 or 
K63-linked ubiquitin chains, and previous analysis has found that 
phosphorylation of OPTN by TANK-binding kinase 1 (TBK1) 
enhances its binding to ubiquitin chains (52). Phosphorylation 
of Ser473 not only enhanced affinity of OPTN to longer K63 chains 
but also promoted binding to other linkage types, which may 
not be relevant to mitophagic signaling in neurons (24, 52). Our 
findings of defined substrates and specific accumulation of K63-
linked ubiquitin chain types in neurons will be beneficial to studies 
underway to reconstitute mitophagy mechanisms in vitro (53, 54) 
that may shed light on the initial steps of ubiquitin receptor re-
cruitment to mitochondria. It was recently suggested that ubiq-
uitin chains alone are sufficient to stimulate mitophagy (55), and our 
findings also lend tractability to undertake genetic analysis as to 
whether ubiquitylation of specific substrates is critical for mito-
phagy or not. FKBP8 has also been reported to act as mitophagy 
receptor in HeLa cells via an N-terminal LC3-interacting region 
that binds strongly to LC3A; however, this was independent of 
Parkin activation (56), and future studies should be directed at 
its role in mitophagy in neurons in light of our discovery of Parkin- 
dependent ubiquitylation.
A recent study has reported that two protein kinases, cyclin 
G-associated kinase (GAK) and PRKC, are previously unknown 
regulators of Parkin-independent mitophagy and recruit ULK1 to 
autophagosome structures close to mitochondria (57). While we 
did not detect either GAK or PRKC, we did detect multiple ki-
nases in our mitochondrial enriched fractions that were ubiqui-
tylated including PRKC, PRKC, and PRKC isoforms, and in 
future work, it will be important to determine whether these and 
other kinases recruited to mitochondria regulate AO-induced mito-
phagy in neurons (table S5). Our analysis has also highlighted 
PINK1-independent and Parkin- independent ubiquitylation sites 
following AO stimulation. While BCL2/adenovirus E1B 19 kDa 
protein-interacting protein 3-like (NIX/BNIP3) and FUN14 domain- 
containing protein 1 (FUNDC1) receptor-mediated mitophagy 
have been linked to mitochondrial turnover during metabolic re-
programming or hypoxia, very little is known on PINK1-independent 
ubiquitin- mediated mechanisms regulating mitophagy (5). Our 
discovery of clear-cut PINK1-independent substrates suggests that 
there are parallel ubiquitin signaling pathways that are activated 
alongside PINK1- Parkin in neurons following AO treatment. 
We have compared our proteome dataset in neurons with the 
UbiHub online database (58) and found 40 E2, 165 “simple” E3, 
and 155 “complex” E3 components that are present within our 
mitochondrial-enriched neuron fractions, and we have deposited 
these data together with all detected ubiquitylation sites in a search-
able online database that we have termed MitoNUb (https://shiny.
compbio.dundee.ac.uk/MitoNUb/). Only two E3s, Mitochondrial 
ubiquitin ligase activator of NFKB 1 (MUL1) and F-box/LRR-re-
peat protein 4 (FBXL4), are located within the mitochondria, and 
the remainder are cytosolic; in future work, it will be interesting to 
define those that may be recruited and activated at the mitochon-
dria upon AO treatment.
Intriguingly, DJ1 ubiquitylation was reduced by AO at Lys93 and, 
to a lesser extent, at Lys130 (fig. S7B). Both sites are highly conserved 
and lie close to Cys106 that is modified under oxidative stress condi-
tions, thereby stimulating DJ1 recruitment from the cytosol to the 
mitochondria (fig. S16A) (59). Patients with DJ1 mutations resem-
ble PINK1 and Parkin patients (60); however, we observed that the 
reduction of DJ1 ubiquitylation at Lys93 was PINK1 independent 
(fig. S16B), and in future work, it will be interesting to determine 
the mechanism of the functional impact of DJ1 ubiquitylation in the 
context of mitophagic signaling. We also observed many other diGLY 
sites that were down-regulated following mitochondrial depolarization, 
suggesting that mitochondrial depolarization may alter the activity 
of Deubiquitinating enzymes (DUBs) at the mitochondria by an as 
yet unknown mechanism.
Overall, this study together with previous findings in human iNeurons 
(18) provides a common signature of ubiquitylation events occur-
ring in neuronal mitochondria that can be used to investigate Parkin 
activity in other neuronal cell types including dopaminergic neurons. 
The identification of a specific set of sites targeted by endogenous 
Parkin in cell types relevant to Parkinson’s will provide impetus to the 
development of facile proteomic and cell-based assays to monitor 
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activate PINK1 and Parkin as a potential therapeutic strategy in 
PD (61).
MATERIALS AND METHODS
Antibodies for biochemical studies
The following primary antibodies were used: anti-Parkin phospho- 
Ser65 rabbit monoclonal antibody was raised by Epitomics/Abcam 
in collaboration with the Michael J. Fox Foundation for Research (please 
contact tools@michaeljfox.org for questions). The following anti-
bodies were used: CISD1 (Cell Signaling Technology and Proteintech), 
glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz Biotechnology), 
ubiquitin (BioLegend), CPT1 (Abcam), HK1 (Thermo Fisher Scientific 
and Cell Signaling Technology), GK (Abcam), DCAKD (Aviva Systems 
Biology), ABCD3 (Aviva Systems Biology), ACSL1 (Cell Signaling 
Technology), ACSL6 (Sigma- Aldrich), AGPAT5 (Abcam), MARC2 
(Sigma-Aldrich), CYB5B (Novus Biologicals), CYB5R3 (Sigma-Aldrich), 
MFN1 (Abcam), MFN2 (Proteintech and Abcam), RHOT2 (Protein-
tech), TOMM70 (Aviva Systems Biology), SLC25A46 (Proteintech), 
FAM213A (Novus Biologicals), MAO-A (Proteintech), MAO-B 
(Abcam), HSDL1 (Proteintech), CAMK2 (Thermo Fisher Scientific), 
CAMK2 (Thermo Fisher Scientific), DCAMKL2 (Abcam), CAD 
(Novus), PRKC (Proteintech), ATAD1/Thorase (NeuroMab), TDRKH 
(Proteintech), FBXO41 (Proteintech), SNX3 (Sigma-Aldrich), CNN3 
(Sigma-Aldrich), SH3BP4 (Novus Biologicals), MAPRE2 (Proteintech), 
RAB5C (MyBioSource), p23 (Thermo Fisher Scientific), VPS35 
(Abcam), OPA1 (Cell Signaling Technology), Rab8A (Cell Signaling 
Technology), Rab8A phospho-Ser111 (Abcam), VDAC (Cell Signaling 
Technology), and horseradish-peroxidase–conjugated secondary 
antibodies (Sigma- Aldrich).
Materials and reagents
HaloLink resin was purchased from Promega. All mutagenesis was 
carried out using the QuikChange site-directed mutagenesis method 
(Stratagene) with KOD polymerase (Novagen). All DNA constructs 
were verified by MRC Protein Phosphorylation and Ubiquitylation 
Unit (PPU) DNA Sequencing Service, School of Life Sciences, Uni-
versity of Dundee, using DYEnamic ET terminator chemistry 
(Amersham Biosciences) on Applied Biosystems automated DNA 
sequencers. DNA for bacterial protein expression was transformed 
into E. coli BL21 DE3 RIL (CodonPlus) cells (Stratagene). Stock solu-
tions of antimycin A (Sigma-Aldrich) and oligomycin (Sigma- 
Aldrich) were used for experiments in cells. Unless otherwise specified, 
general reagents and chemicals were from Sigma-Aldrich (Merck), 
and cell culture reagents were from Gibco/Invitrogen (Thermo Fisher 
Scientific). All cDNA plasmids, antibodies, and recombinant pro-
teins generated in-house for this study are available on request through 
our dedicated reagents website: https://mrcppureagents.dundee.ac.uk/. 
All newly generated resources are being registered with rrids.org/, 
and research resource identifier are included in the list of the key 
resources in the supplementary materials.
Primary cortical neuron preparation and culture
Primary mouse cortical neurons were isolated from the brains of 
C57BL/6J embryos of either sex at E16.5. Embryonic cortices were 
collected in Hanks’ balanced salt solution, and cells were dissociated 
by incubation with trypsin-EDTA (#25300-054, Gibco) at 37°C. Cells 
were then diluted in Neurobasal medium containing B27 sup-
plement, GlutaMAX, and penicillin-streptomycin and plated at a 
density of 5.0 × 105 cells per well on six-well plates coated with po-
ly-l-lysine (0.1 mg ml−1; Sigma-Aldrich). Neurons were cultured at 
37°C in a humidified incubator with 5% CO2. Every 5 days, the me-
dium was replaced with fresh medium containing B27. To depolar-
ize mitochondrial membrane potential in neurons, cultures were 
treated for 5 hours with 10 M antimycin A (Sigma-Aldrich) and 
1 M oligomycin (Sigma-Aldrich) in DMSO at 37°C. A detailed pro-
tocol describing the preparation of primary cortical mouse neurons 
has been reported (dx.doi.org/10.17504/protocols.io.bswanfae).
Immunofluorescence and confocal microscopy
Mouse cortical neurons were seeded on poly-l-lysine–coated glass 
coverslips and were fixed for 20 min on ice in 4% paraformaldehyde 
(Sigma-Aldrich)/4%sucrose solution in phosphate-buffered saline 
(PBS; Gibco). Neurons were permeabilized for 1 hour in blocking 
solution, containing 0.2% Triton X-100 (Sigma-Aldrich) and 10% 
donkey serum (Sigma-Aldrich), and incubated overnight at 4°C with 
the primary antibodies MAP2 (1:100; Sigma-Aldrich, M2320) and 
GFAP (1:100; Abcam, ab7260) in blocking solution. Then, neurons 
were washed with PBS and incubated for 1 hour at room tempera-
ture with Hoechst and with anti-rabbit or anti-mouse secondary 
antibodies conjugated with Alexa Fluor 488 and Alexa Fluor 594 
(1:1000; Thermo Fisher Scientific) in blocking solution. After three 
washes in PBS, neurons were mounted using VECTASHIELD. Im-
ages were acquired with an LSM 710 laser scanning confocal micro-
scope (ZEISS; Plan-Neofluar ×40 objective) using ZEISS Zen Software. 
Images were quantified for MAP2-positive and GFAP-positive cells 
using Volocity 3D Image Analysis Software (Quorum Technologies, 
Ontario) using a custom written protocol.
High-resolution respirometry of primary neurons
Primary mouse cortical neurons from PINK1 KO embryos and 
their wild-type littermates were cultured for DIV21. Neurons were 
washed twice with PBS and treated with 0.05% trypsin for 15 min, after 
which trypsin was neutralized with Dulbecco’s modified Eagle’s 
medium (DMEM)/nutrient mixture F-12 medium. Neurons were 
gently spun down (300g for 3 min), and the cells of two wells 
(of six well plates) were resuspended in DMEM F12 and used for 
high- resolution respirometry. After cell number determination, 
cells were gently spun down (300g for 3 min). The supernatant was 
aspirated, and 50 l of MiR05 medium [110 mM sucrose, 60 mM 
lactobionic acid, 0.5 mM EGTA, 3 mM MgCl2, 20 mM taurine, 10 mM 
KH2PO4, 20 mM Hepes adjusted to pH 7.1 with KOH at 30°C, 
and bovine serum albumin (BSA; 1 g/liter) essentially fatty acid 
free] was added to the pellet. Pellets were resuspended (using a 
1-ml tip to avoid damaging the cells) and placed in an oxygraphic 
chamber thermostated at 37°C with continuous stirring (Oxygraph-2k, 
Oroboros Instruments, Innsbruck, Austria). Mitochondrial respira-
tory rates were assessed using the substrate-uncoupler-inhibitor 
titration protocol number 2 (SUIT-002) (62). Briefly, after residual 
oxygen consumption (ROX; in the presence of 2.5 mM adenosine 
diphosphate) in the absence of endogenous fuel, substrates were 
measured; fatty acid oxidation pathway state (F) was measured by 
adding 0.1 mM malate and 0.2 mM octanoyl carnitine (OctMP). 
Membrane integrity was then evaluated by adding 10 M cytochrome c 
(OctMcP). Subsequent to the F-pathway state, the reduced form 
of nicotinamide adenine dinucleotide electron transfer-pathway 
state (FN) was studied by adding 2 mM malate (OctMP), 5 mM 
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succinate (OctPGMSP) was added to subsequently stimulate the S 
pathway (FNS), followed by 10 mM glycerophosphate (OctPGMSGpP) 
to reach convergent electron flow in the FNSGp pathway to the 
Q-junction. Uncoupled respiration was then evaluated by realizing a 
titration with CCCP (OctPGMSGpE). Complex I was then inhibited 
with 0.5 M rotenone (SGpE), and last, ROX was measured by add-
ing 2.5 M antimycin A. ROX was then subtracted from all respira-
tory states to obtain mitochondrial respiration. Results are expressed 
in pmol · s−1 · 106 cells. The P/E control ratio, which reflects the 
control by coupling and limitation by the phosphorylation system, 
was subsequently calculated by dividing the OctPGMSGpP value by 
the OctPGMSGpE value.
Isolation of mitochondrial enriched membrane fraction
Cells were collected in ice-cold PBS containing sodium orthovana-
date (1 mM), sodium glycerophosphate (10 mM), sodium fluoride 
(50 mM), sodium pyrophosphate (10 mM), phenylmethylsulfonyl 
fluoride (PMSF; 0.1 mM) protease inhibitor cocktail, and 200 mM 
chloroacetamide and centrifuged at 500g for 3 min at 4°C. Cell pellets 
were resuspended and lysed in homogenization buffer containing 
250 mM sucrose, 300 mM imidazole, 1 mM sodium orthovanadate, 
phosphatase inhibitor cocktail 3 (Sigma-Aldrich), and protease inhib-
itor cocktail (Roche) and supplemented with 200 mM chloroacetamide 
at 4°C. Cells were disrupted using a metal handheld homogenizer 
(40 passes), and the lysates were clarified by centrifugation (2000 rpm 
at 4°C for 5 min). The supernatant was harvested and subjected to 
an additional centrifugation step at 40000 rpm for 1 hour at 4°C. The 
resulting pellet containing the membrane-enriched fraction that was 
resuspended in Mitobuffer [270 mM sucrose, 20 mM Hepes, 3 mM 
EDTA, 1 mM sodium orthovanadate, 10 mM sodium -glycerophosphate, 
50 mM sodium fluoride, 5 mM sodium pyrophosphate (pH 7.5), and 
protease inhibitor cocktail (Roche) supplemented with 200 mM 
chloroacetamide at 4°C] and solubilized with a probe sonicator (5 s, 
20% amplitude). A detailed protocol describing the isolation of 
mitochondrial-enriched fractions from cortical mouse neurons has 
been reported (dx.doi.org/10.17504/protocols.io.bxjupknw).
Whole-cell lysate preparation
Primary cortical neurons and SH-SY5Y cells were sonicated in lysis 
buffer containing tris·HCl (50 mm, pH 7.5), EDTA (1 mM), EGTA 
(1 mM), Triton (1%, w/v), sodium orthovanadate (1 mM), sodium 
glycerophosphate (10 mM), sodium fluoride (50 mM), sodium pyro-
phosphate (10 mM), sucrose (0.25 mM), benzamidine (1 mM), PMSF 
(0.1 mM) protease inhibitor cocktail (Roche), phosphatase inhib-
itor cocktail 2 and 3 (Sigma-Aldrich), and chloroacetamide (200 mM). 
Following sonication, lysates were incubated for 30 min on ice. Sam-
ples were spun at 20,800g in an Eppendorf 5417R centrifuge for 30 min. 
Supernatants were collected, and protein concentration was deter-
mined by using the Bradford kit (Pierce). A detailed protocol de-
scribing the lysis of primary cortical mouse neurons has been 
reported (dx.doi.org/10.17504/protocols.io.bsvcne2w).
Ubiquitin enrichment
For ubiquitylated protein capture, Halo-tagged UBDs of TUBE, 
multi-DSK (yeast Dsk1 ubiquitin binding protein) and multi-DSK 
mutant were incubated with HaloLink resin (200 l; Promega) in 
binding buffer [50 mm tris·HCl (pH 7.5), 150 mm NaCl, and 0.05% 
NP-40] overnight at 4°C. Membrane-enriched fraction (400 g) was 
used for pulldown with HALO-UBDs. Halo tube beads (20 l) were 
added to neuronal membrane enrichment and incubated ON at 
4°C. The beads were washed three times with lysis buffer containing 
0.25 mM NaCl and eluted by resuspension in 1× lithium dodecyl 
sulfate (LDS) sample buffer (20 l) with 1 mM dithiothreitol (DTT) 
or 2.5% 2-mercaptoethanol. The method for ubiquitin capture has 
previously been reported for Halo-tagged UBDs of TUBE (63) and 
multi-DSK (yeast Dsk1 ubiquitin binding protein) (64).
PINK1 immunoprecipitation
For immunoprecipitation of endogenous PINK1, 500 g of whole-
cell lysate or membrane fraction was incubated overnight at 4°C with 
10 g of PINK1 antibody (S774C; MRC PPU Reagents and Services) 
coupled to Protein A/G beads (10 l of beads per reaction; Amintra) 
as previously reported (65). The immunoprecipitants were washed 
three times with lysis buffer containing 150 mM NaCl and eluted by 
resuspending in 10 l of 2× LDS sample buffer and incubating at 
37°C for 15 min under constant shaking (2000 rpm) followed by the 
addition of 2.5% (by volume) 2-mercaptoethanol.
Immunoblotting
All the samples were subjected to SDS–polyacrylamide gel electro-
phoresis (SDS-PAGE; bis-tris 4 to 12% gels), CAD, and Nav1 proteins 
were separated by using tris-acetate (3 to 8% gels), and all the gels 
were transferred onto Protran 0.45 polyvinylidene difluoride mem-
branes (Immobilon-P). Membranes were blocked for 1 hour at room 
temperature with 5% nonfat milk or BSA in tris-buffer saline + 
0.1% Tween20 [TBS-T; 50 mM tris·HCl and 150 mM NaCl (pH 7.5)] 
containing 0.1% Tween-20 and probed with the indicated antibod-
ies overnight at 4°C. Detection was performed using horseradish 
peroxidase–conjugated secondary antibodies and enhanced chemi-
luminescence reagent. A detailed protocol describing the biochemical 
analysis of PINK1-Parkin pathway in primary cortical neurons by 
immunoblotting has been reported (dx.doi.org/10.17504/protocols.
io.bswanfae).
Parkin ubiquitylation assay
In vitro ubiquitylation assays were performed using recombinant pro-
teins purified from E. coli unless stated otherwise. Wild-type Parkin 
(0.75 M) was incubated for 30 min at 37°C in a thermo shaker at 
1000 rpm with 0.36 M wild-type or kinase-inactive (D359A) Maltose- 
binding protein (MBP)–TcPINK1 (T. castaneum PINK1) in 15 l 
of kinase buffer [50 mM tris-HCl (pH 7.5), 0.1 mM EGTA, 10 mM 
MgCl2, and 0.1 mM ATP]. The ubiquitin master mix (50 mM 
tris-HCl, 10 mM MgCl2, 2 mM ATP, 0.12 M His-UbE1 expressed 
in Sf21 insect cells, 1 M human UbE2L3, 50 M Flag-ubiquitin, 
and 0.5 M substrate) was added to a final volume of 30 l, and the 
reaction was incubated at 37°C for 30 min in a thermo shaker at 
1000 rpm. Reactions were terminated by the addition of 4× LDS 
loading buffer, and 5 l of the final volume was resolved using SDS-
PAGE on a 4 to 12% bis-tris gel and immunoblotted using an anti- 
FLAG, anti-His, or antibodies against the substrate being tested.
Samples were resolved using SDS-PAGE on 4 to 12% bis-tris gels 
in Mops buffer and transferred to nitrocellulose membranes. Mem-
branes were blocked with 5% (w/v) milk powder in TBS + 0.1% 
Tween-20 (TBS-T) for 1 hour at room temperature and then immuno-
blotted against the primary antibody in 5% (w/v) BSA/TBS-T at 5° 
to 7°C overnight. Protein bands were detected by blotting against 
secondary antibodies labeled with 800- or 680-nm fluorophores in 
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A detailed protocol describing the expression of MBP-TcPINK1 
has been reported (dx.doi.org/10.17504/protocols.io.bsrend3e). A 
detailed protocol describing the recombinant Parkin in vitro ubiq-




His6-SUMO cleaved wild-type Parkin was expressed on the basis 
of the method (12). Briefly, plasmids were transformed in BL21- 
CodonPlus (DE3)-RIL E. coli, overnight cultures were prepared and 
used to inoculate 12× 1 liter of LB medium containing carbenicillin 
(50 g/ml) and 0.25 mM ZnCl2. These were initially incubated at 
37°C until the cultures reached an optical density at 600 nm (OD600) 
of 0.4; the incubator temperature was lowered to 15°C, and once 
cultures reached an OD600, of 0.8 to 0.9 expression was induced by 
the addition of 25 M isopropyl--d-thiogalactopyranoside (IPTG). 
After overnight incubation (16 hours), cells were pelleted by cen-
trifugation (4200g, 25 min), the medium was removed, and the cell 
pellet was suspended in lysis buffer [50 mM tris-HCl (pH 7.5), 250 mM 
NaCl, 15 mM imidazole (pH 7.5), and 0.1 mM EDTA with 1 M 
4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) 
and leupeptin (10 g/ml) added]. Cells were burst by sonication; cell 
debris were pelleted by centrifugation (35,000g for 30 min at 4°C), 
and the supernatant was incubated with Ni–nitrilotriacetic acid 
(Ni-NTA) resin for 1 hour at 5° to 7°C. Ni-NTA resin was washed 
five times in 7× the resin volume of lysis buffer and twice in 7× the 
resin volume of cleavage buffer [50 mM tris (pH 8.3), 200 mM NaCl, 
10% glycerol, and 1 mM TCEP (tris(2-carboxyethyl)phosphine)]. 
Parkin was cleaved from the resin at 4°C overnight by the addition of 
a 1:5 mass ratio of His-SUMO/Sentrin Specific Peptidase 1 (SENP1) to 
total protein mass bound to the resin. After cleavage, Parkin was 
concentrated and further purified using size exclusion chromatog-
raphy on a Superdex S200 column (16/600). Parkin was eluted after 
80- to 90-ml fractions were pooled and concentrated, and the purity 
was tested using SDS-PAGE.
Cpt1
A catalytic domain-containing fragment of Cpt1 (residues 145 
to 773; missing the transmembrane domain) was expressed as His- 
SUMO–tagged fusion protein. The cDNA of the protein coding 
sequences was subcloned into pET15b plasmid vectors and trans-
formed into BL21-DE3. A 150-ml starter culture was inoculated 
using a swipe from the cell plate and incubated at 37°C overnight. 
One liter of LB medium (12×) containing carbenicillin (50 g/ml) 
was each inoculated with 20 ml of starter culture. When cell cul-
tures reached an OD600 of 0.8 to 0.9 and a temperature of 15°C, 
protein expression was induced by the addition of 50 M IPTG. Cell 
cultures were left to express at 15°C overnight (~16 hours) and then 
harvested by centrifugation at 5020g for 25 min; the medium was 
removed, and the cell pellet was suspended in 25 ml per 1 liter (~5-ml 
pellet) of lysis buffer [50 mM tris-HCl (pH 7.5), 250 mM NaCl, 
15 mM imidazole (pH7.5), and 0.1 mM EDTA with 1 M AEBSF 
and leupeptin (10 g/ml) added]. Cells were burst by sonication at 
50% amplitude on ice using 6× 15 s pulses; glycerol (10%) was add-
ed, and the lysis buffer was made up to 500 mM NaCl. Cell debris 
were pelleted by centrifugation at 35,000g and 4°C for 30 min; then, the 
supernatant layer was transferred to Ni-NTA resin. The superna-
tant was incubated with Ni-NTA resin for 1 hour at 5° to 7°C and 
washed six times in 7× the resin volume of wash buffer [50 mM 
tris-HCl (pH 7.5), 500 mM NaCl, 15 mM imidazole (pH 7.5), 0.5 mM 
TCEP, and 10% glycerol]; then, His-SUMO-Cpt1 145-773 was 
eluted by incubation with 4× the resin volume of elution buffer 
(wash buffer containing 400 mM imidazole) at 5° to 7°C for 1 hour. 
The solvent layer was dialyzed against 5 liters of dialysis buffer 
[50 mM tris-HCl (pH 7.5), 200 mM NaCl, 0.5 mM TCEP, and 10% 
glycerol] overnight at 4°C with a 1:10 mass ratio of His-SENP1:eluted 
protein mass added. Uncleaved Cpt1 and contaminants were de-
pleted by incubating with Ni-NTA resin for 1 hour at 5° to 7°C. The 
solvent layer was concentrated and purified using size exclusion 
chromatography in dialysis buffer using a 16/600 Superdex SD200 
column. Fractions containing Cpt1 145-773 (peak at ~75 ml) were 
pooled and concentrated to give the recombinant.
GST-Miro1
GST-Miro1 cDNA was subcloned into a pGEX6 plasmid vector and 
transformed into BL21-CodonPlus (DE3)-RIL E. coli. A 150-ml starter 
culture was inoculated using a swipe from the cell plate and incu-
bated at 37°C overnight. One liter of LB medium (12×) containing 
carbenicillin (50 g/ml) was each inoculated with 20 ml of started 
culture. When cell cultures reached an OD600 of 0.8 to 0.9 and a tem-
perature of 15°C, protein expression was induced by the addition of 
50 M IPTG. Cell cultures were left to express at 15°C overnight 
(~16 hours) and then harvested by centrifugation at 5020g for 25 min; 
the medium was removed, and the cell pellet was suspended in 
25 ml per 1 liter (~5-ml pellet) of lysis buffer [50 mM tris-HCl (pH 7.5), 
250 mM NaCl, 1 mM -mercaptoethanol, and 0.1 mM EDTA with 
1 M AEBSF and leupeptin (10 g/ml) added]. Cells were burst by 
sonication at 50% amplitude on ice using 6× 15-s pulses. Cell debris 
were pelleted by centrifugation at 35,000g and 4°C for 30 min; then, 
the supernatant layer was transferred to glutathione resin. The 
supernatant was incubated with the GSH resin for 1 hour at 5° to 
7°C; the GSH resin was washed six times in 14× the resin volume of 
wash buffer [50 mM tris-HCl (pH 7.5), 200 mM NaCl, 0.5 mM 
TCEP, and 10% glycerol], and the protein was eluted by incubation 
with wash buffer containing 10 mM glutathione for 1 hour at 5° to 
7°C. The eluted supernatant was dialyzed against 5  liters of wash 
buffer at 5° to 7°C overnight and concentrated, and the final sample 
was flash-frozen.
ACSL1 and SNX3
Cleaved ACSL1 (missing the N-terminal transmembrane domain) and 
SNX3 were expressed as a His6-SUMO tagged constructs. cDNA of 
the protein coding sequences were subcloned into pET15b plasmid 
vectors and transformed into BL21-CodonPlus (DE3)-RIL E. coli. A 
100-ml starter culture was inoculated using a swipe from the cell 
plate and incubated at 37°C overnight. One liter of LB medium (6×) 
containing carbenicillin (50 g/ml) was each inoculated with 20 ml 
of started culture. When cell cultures reached an OD600 of 0.8–0.9 
and a temperature of 15°C, protein expression was induced by the 
addition of 100 M IPTG. Cell cultures were left to express at 15°C 
overnight (~16 hours) and then harvested by centrifugation at 5020g 
for 25 min; the medium was removed, and the cell pellet was 
suspended in 25 ml per 1 liter (~5-ml pellet) of lysis buffer [50 mM 
tris-HCl (pH 7.5), 250 mM NaCl, 15 mM imidazole (pH 7.5), and 
0.1 mM EDTA with 1 M AEBSF and leupeptin (10 g/ml) added]. 
Cells were burst by sonication at 50% amplitude on ice using 6× 
15-s pulses; glycerol (10%) was added, and the lysis buffer was made 
up to 500 mM NaCl. Cell debris were pelleted by centrifugation at 
35,000g and 4°C for 30 min; then, the supernatant layer was trans-
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Ni-NTA resin for 1 hour at 5° to 7°C, washed six times in 7× the 
resin volume of wash buffer [50 mM tris-HCl (pH 7.5), 500 mM 
NaCl, 15 mM imidazole (pH 7.5), 0.5 mM TCEP, and 10% glycerol] 
and then two times in 7× the resin volume of cleavage buffer [50 mM 
tris-HCl (pH 7.5), 200 mM NaCl, 0.5 mM TCEP, and 10% glycer-
ol]. The resin was incubated overnight without agitation at 4°C in 
4× the resin volume of cleavage buffer with a 1:10 mass ratio of 
His-Senp1:bound protein. The solvent layer was depleted against a 
further 1 ml of Ni-NTA resin at 5° to 7°C for 1 hour. The final 
solution was concentrated, flash-frozen in liquid nitrogen, and 
stored at −80°C.
MBP-CamK2 and MBP-CamK2
CamK2 and CamK2 were expressed as MBP-tagged constructs. 
cDNAs of the protein coding sequences were subcloned into pM-
EX3Cb plasmid vectors and transformed into BL21-CodonPlus 
(DE3)-RIL E. coli. A 100-ml starter culture was inoculated using a 
swipe from the cell plate and incubated at 37°C overnight. One liter 
of LB medium (6×) containing carbenicillin (50 g/ml) was each 
inoculated with 20 ml of started culture. When cell cultures reached 
an OD600 of 0.8 to 0.9 and a temperature of 15°C, protein expres-
sion was induced by the addition of 400 M IPTG. Cell cultures were 
left to express at 15°C overnight (~16 hours) and then harvested by 
centrifugation at 5020g for 25 min; the medium was removed, and 
the cell pellet was suspended in 25 ml per 1 liter (~5-ml pellet) of 
lysis buffer [50 mM tris-HCl (pH 7.5), 250 mM NaCl, and 0.1 mM 
EDTA with 1 M AEBSF and leupeptin (10 g/ml) added]. Cells 
were burst by sonication at 50% amplitude on ice using 6× 15-s 
pulses; glycerol (10%) was added, and the lysis buffer was made up to 
500 mM NaCl. Cell debris were pelleted by centrifugation at 35,000g 
and 4°C for 30 min. The supernatant was incubated with amylose 
resin for 1 hour at 5° to 7°C, washed six times in 7× the resin volume 
of lysis buffer, and then eluted in elution buffer [50 mM tris-HCl 
(pH 7.5), 500 mM NaCl, 10 mM maltose, 0.5 mM TCEP, and 10% 
glycerol]. The eluted sample was dialyzed overnight against 5 liters 
of sample buffer [50 mM tris-HCl (pH 7.5), 0.1 mM EGTA, 150 
mM NaCl, 0.1% ß-mercaptoethanol, 270 mM sucrose, and 0.03% 
Brij-35]. The final solution was concentrated, flash-frozen, in liquid 
nitrogen, and stored at −80°C.
GST-Fam213A, GST–MAO-A, and GST–MAO-B
Fam213A, MAO-A, and MAO-B were expressed as GST-tagged con-
structs. cDNAs of the protein coding sequences were subcloned into 
pGEX6 plasmid vectors and transformed into BL21-CodonPlus 
(DE3)-RIL E. coli. A 100-ml starter culture was inoculated using a 
swipe from the cell plate and incubated at 37°C overnight. One liter 
of LB medium (6×) containing carbenicillin (50 g/ml) was each 
inoculated with 20 ml of started culture. When cell cultures reached 
an OD600 of 0.8 to 0.9 and a temperature of 15°C, protein expression 
was induced by the addition of 50 M IPTG. Cell cultures were left 
to express at 15°C overnight (~16 hours) and then harvested by cen-
trifugation at 5020g for 25 min; the medium was removed, and the 
cell pellet was suspended in 25 ml per 1 liter (~5-ml pellet) of lysis 
buffer [50 mM tris-HCl (pH 7.5), 250 mM NaCl, and 0.1 mM EDTA 
with 1 M AEBSF and leupeptin (10 g/ml) added]. Cells were 
burst by sonication at 50% amplitude on ice using 6× 15-s pulses; 
glycerol (10%) was added, and the lysis buffer was made up to 500 mM 
NaCl. Cell debris were pelleted by centrifugation at 35,000g and 4°C 
for 30 min. The supernatant was incubated with GSH resin for 
1 hour at 5° to 7°C, washed six times in 7× the resin volume of lysis 
buffer, and then eluted in elution buffer [50 mM tris-HCl (pH 7.5), 
500 mM NaCl, 10 mM reduced glutathione, 0.5 mM TCEP, and 
10% glycerol]. The eluted sample was dialyzed overnight against 
5 liters of sample buffer [50 mM tris-HCl (pH 7.5), 0.1 mM EGTA, 
150 mM NaCl, 0.1% -mercaptoethanol, 270 mM sucrose, and 
0.03% Brij-35]. The final solution was concentrated, flash-frozen in 
liquid nitrogen, and stored at −80°C.
Reconstitution of Parkin ubiquitylation activity in vitro 
in purified mitochondria
Mitochondrial isolation
Wild-type and PINK1 KO MEFs or Hela cells were stimulated with 
10 M antimycin and 1 M oligomycin (4 hours for MEFs and 
2 hours for HeLa) to induce PINK1 stabilization on mitochondrial 
outer membrane. Cell were washed twice with ice-cold PBS and 
resuspended in hypotonic buffer containing 20 mM Hepes (pH 7.8), 
5 mM KCl, 1.5 mM MgCl2, 2 mM DTT, 1 mM PMSF, and protease 
inhibitor cocktail (Roche) for 15 min on ice. Cells were disrupted 
using a metal handheld homogenizer (45 passes for MEFs and 25 passes 
for HeLa); then, 2.5× mannitol-sucrose buffer [2.5× MSH; 20 mM 
Hepes (pH 7.8), 525 mM mannitol, 175 mM sucrose, 5 mM EDTA, 
1 mM PMSF, and protease inhibitor cocktail (Roche)] was added to 
the disrupted cells, and the cell homogenates were clarified by cen-
trifugation (700g at 4°C for 10 min) to remove nuclei and cell 
debris. Supernatants were collected and spun down at 9000g for 
10 min. Mitochondrial pellets were resuspended and washed twice 
in 1× MSH [20 mM Hepes (pH 7.8), 210 mM mannitol, 70 mM 
sucrose, 2 mM EDTA, 1 mM PMSF, and protease inhibitor cocktail 
(Roche)] and centrifuged at 9000g for 10 min at 4°C. In the final 
step, mitochondrial pellets were resuspended in Mito ubiquitylation 
buffer [MUB; 50 mM tris HCl (pH 7.5), 70 mM sucrose, 210 mM 
sorbitol, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, and 
10 mM sodium 2-glycerophosphate]. A detailed protocol describ-
ing the purification of mitochondria for in vitro ubiquitylation assay 
has been reported (dx.doi.org/10.17504/protocols.io.bxmypk7w).
Ubiquitylation assay
Mitochondria were isolated from cells and resuspended in MUB. 
Mitochondrial preparations (5 g) were used as substrates for the in vitro 
ubiquitylation assay. Wild-type Parkin (1 M) was incubated with 0.1 M 
His-UbE1 expressed in Sf21 insect cells, 1 M human UbE2L3, 
and 30 M ubiquitin for 120 (MEFs) or 90 min (HeLa) at 30°C in a 
thermo shaker at 1000 rpm in 50 l of reaction buffer [50 mM tris-HCl 
(pH 7.5), 5 mM MgCl2, 0.5 mM TCEP, and 2 mM ATP]. Reactions 
were terminated by the addition of 4× LDS loading buffer, containing 
10% 2-mercaptoethanol. The final volume (20 l) was resolved using 
SDS-PAGE on a 4 to 12% bis-tris gel and immunoblotted using 
antibodies against the substrate being tested. A detailed protocol de-
scribing the in vitro ubiquitylation assay using purified mitochon-
dria has been reported (dx.doi.org/10.17504/protocols.io.bxmypk7w).
Online database
diGLY peptide TMT ratios were normalized to the total proteome. 
For differential expression, these data were normalized to median in 
each sample to account for sample-to-sample variation. Differential 
expression was performed with limma (66) using logarithms of nor-
malized peptide ratios. P values were corrected for multiple tests 
using Benjamini-Hochberg method. All analyses were done in R, 
and the code is available at https://github.com/bartongroup/MG_
UbiMito (doi 10.5281/zenodo.5152822). An online interactive tool 
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https://shiny.compbio.dundee.ac.uk/MitoNUb/ (RRID: SCR_021544). 
It allows for selection of peptides based on differential expression 
significance, fold change, presence or absence in MitoCarta, and/or 
total proteome. Selected peptides provide instantaneous Gene On-
tology term and Reactome pathway enrichment results.
Proteomics—Sample preparation for copy number analysis
Three biological replicates of C57Bl/6J mouse cortical neurons 
(technical duplicates each) were treated for 5 hours with 10 M 
antimycin A and 1 M oligomycin (AO) in DMSO at 37 °C in a 
incubator with 5% CO2. Neurons were lysed in lysis buffer containing 
tris·HCl (10 mM, pH 8.0), SDS (2%, w/v), sodium orthovanadate 
(1 mM), sodium glycerophosphate (10 mM), sodium fluoride 
(50 mM), sodium pyrophosphate (5 mM), protease inhibitor cock-
tail (Roche), and microcystin-LR (1 g/ml). Lysates were boiled for 
10 min at 95°C, followed by Bioruptor sonication for 10 min (30-s 
on and 30-s off, 10 cycles) at 4°C. Samples were spun at 20,000g in 
a centrifuge at 4°C for 20  min. Supernatants were collected, and 
protein concentration was determined by using the BCA kit 
(Pierce). Fifty micrograms of protein for each sample (n = 6 AO and 
n = 6 DMSO) and 300 g of pooled cortical neurons for deep pro-
teomic profile of cortical neurons were aliquoted and subjected to 
S-Trap assisted workflow as described in (67). Briefly, protein lysate 
was reduced with 10 mM TCEP and alkylated with 40 mM Iodoac-
etamide. Samples were then processed using S-Trap micro and mini 
columns. Samples were purified by washing with S-Trap wash 
buffer [100 mM Triethylammonium bicarbonate buffer (TEABC) 
(pH 7.2) in 90% methanol] four times. On-column Lys-C ± tryp-
sin was added at 1:20 ratio and incubated at 47°C for 1.2 hours and 
then incubated overnight at room temperature. Peptides were eluted 
with sequential elution using 50 mM TEABC buffer, 0.15% formic 
acid (v/v), and 80% acetonitrile (ACN) in 0.15% formic acid (v/v); elu-
ates were pooled and vacuum-dried. Pooled cortical neuron tryptic pep-
tide digests were further fractionated using high-pH reversed-phase 
liquid chromatography (RPLC) fractionation, and 45 fractions were 
used for data-dependent acquisition (DDA) analysis. OA and DMSO 
treated samples were then dissolved in LC buffer [3% ACN in 0.1% 
formic acid (v/v)], and 2 g of peptide was injected for DIA analysis. 
The main methods are described in a recent study (67).
Proteomics—Copy number total proteomic analysis using 
DDA and DIA
Forty high-pH fractions were analyzed on Orbitrap Exploris 480 mass 
spectrometer coupled in line with Dionex 3000 RSLCnano liquid 
chromatography (LC) system. Each fraction of ~2 g was dissolved 
in 15 l of LC buffer [3% ACN in 0.1% formic acid (v/v)]. Sample 
was injected onto trap column (Acclaim PepMap 2 cm, 3 m particle; 
C18#164569) and separated on a 50-cm analytical column at 300 nl/
min (ES803; 50 cm, C18 2 particle) and directly electrosprayed 
into the mass spectrometer using EASY nanoLC source. An 80-min 
nonlinear gradient was used to separate the peptides with a total run 
time of 100 min for each run. Data were acquired in a DDA mode 
by acquiring full MS at 60,000 resolution at a mass/charge ratio 
(m/z) of 200 and analyzed using Orbitrap mass analyzer. MS2 data 
were acquired at top speed for 2 s to acquire as many data-dependent 
scans by using 1.2-Da isolation window using quadrupole mass filter 
and fragmented using normalized 30% HCD (high-energy collision- 
induced dissociation); the MS fragment ion was measured at 15,000 
resolution at m/z of 200 using Orbitrap mass analyzer. Automatic 
gain control (AGC) targets for MS1 was set at 300% and MS2 at 
100% with a maximum ion-injection accumulation time at 25 and 
80 ms, respectively. For the DIA analysis, 2 g of peptide amount 
from each of the cortical neuron–treated samples (n = 6 AO and 
n = 6 DMSO) was acquired on an Orbitrap Exploris 480 mass spec-
trometer. Peptides were loaded on trap column and eluted on an 
analytical column by using a nonlinear gradient of 120 min and a 
total of 145-min run. MS1 data were acquired at 120,000 resolution 
at m/z of 200 and measured using Orbitrap mass analyzer. Variable 
DIA scheme was used by using a Quadrupole mass filter in the mass 
range of 400 to 1500 m/z. The DIA isolation window and instrument 
parameters were provided in table S1. Peptides were fragmented using 
a normalized steeped HCD collision energy (26, 28, and 30) and 
mea sured at 30,000 resolution at m/z of 200 using Orbitrap mass 
analyzer. AGC target for MS1 was set at 300% and for MS2 was 
set at 3000% with a maximum ion-injection accumulation time of 
25 and 80 ms, respectively.
MS data analysis
DDA raw MS data were processed using Frag pipe software suite 
(version 15.0) using an in-built MS-Fragger search algorithm (68, 69). 
Default closed search workflow was used and searched against 
Mouse UniProt database (March 2021, 34,350 entries). Precursor 
mass tolerance was set at −50 and ±50 ppm (parts per million), and 
fragment mass tolerance was set at 20 ppm. Trypsin as a strict protease 
by allowing a maximum missed cleavage of 2 and peptide length of 
7 amino acid as minimum and 50 amino acid as maximum. Oxida-
tion of Met and protein N-terminal acetylation were considerated 
as variable modifications. Carbamidomethylation of Cys as a fixed 
modification was used. MS1 quantification was performed using 
Ionquant algorithm by allowing match between runs. One percent 
false discovery rate (FDR) at peptide-spectrum match (PSM), pep-
tide, and protein level was applied for the final output files. Protein 
group table was further processed using Perseus software suite to 
estimate copy numbers using histone proteomic ruler (30, 70).
The DDA data were used to generate a spectral library using Spec-
tronaut version 15 (Biognosys) pulsar search engine (71). This library 
was used for the library-based search for DIA data by using the de-
fault search parameters and enabling cross-run normalization. The 
search output protein group table was exported and processed using 
Perseus for further analysis. Student t test was carried out between 
AO and DMSO-treated cortical neurons by applying 1% permutation- 
based FDR for the identification of differentially regulated proteins 
(70). The main methods are described in a recent study (67).
Proteomics—General sample preparation for TMT analysis
Protein extracts lysed in 8 M urea were subjected to disulfide 
bond reduction with 5 mM TCEP (room temperature, 10 min) and 
alkylation with 25 mM chloroacetamide (room temperature, 20 min). 
Methanol-chloroform precipitation was performed before protease 
digestion. Briefly, four parts of neat methanol were added to each 
sample and vortexed, one part chloroform was then added to the sam-
ple and vortexed, and last, three parts water was added to the 
sample and vortexed. The sample was centrifuged at 6000  rpm 
for 2 min at room temperature and subsequently washed twice 
with 100% methanol. Samples were resuspended in 100 mM 3-[4-(2- 
hydroxyethyl)piperazin-1-yl]propane-1-sulfonic acid (EPPS) pH 8.5 
containing 0.1% RapiGest and digested at 37°C for 4 hours with 
LysC protease at a 200:1 protein-to-protease ratio. Trypsin was then 
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incubated for a further 6 hours at 37°C. Samples were acidified with 
1% formic acid for 15 min and subjected to C18 solid-phase extraction 
(Sep-Pak, Waters). The Pierce Quantitative Colorimetric Peptide Assay 
(catalog no. 23275) was used to quantify the digest and to accurately 
aliquot the desired amount of peptides per sample needed for down-
stream application. A detailed protocol describing TMT proteomics 
has been reported (dx.doi.org/10.17504/protocols.io.buyunxww).
Proteomics—Total proteomic analysis using TMT
The procedure is previously described in https://doi.org/10.1016/j.
molcel.2019.11.013. Tandem mass tag labeling of each sample (100 g 
of peptide input) was performed by adding 10 l of the stock (20 ng/l) 
of TMT reagent along with ACN to achieve a final ACN concen-
tration of approximately 30% (v/v). Following incubation at room 
temperature for 1 hour, the reaction was quenched with hydroxyl-
amine to a final concentration of 0.5% (v/v) for 15 min. The TMT- 
labeled samples were pooled together at a 1:1 ratio. The sample was 
vacuum-centrifuged to near dryness and subjected to C18 solid- 
phase extraction (50 mg; Sep-Pak, Waters).
Dried TMT-labeled sample was resuspended in 100 l of 10 mM 
NH4HCO3 (pH 8.0) and fractionated using basic pH reversed-phase 
(BPRP) high-performance LC (HPLC) (72). Briefly, samples were 
offline-fractionated over a 90-min run, into 96 fractions by high-pH 
reverse-phase HPLC (Agilent, LC1260) through an Aeris peptide 
xb-c18 column (Phenomenex; 250 mm by 3.6 mm) with mobile 
phase A containing 5% ACN and 10 mM NH4HCO3 in LC-MS 
grade H2O and mobile phase B containing 90% ACN and 10 mM 
NH4HCO3 in LC-MS grade H2O (both pH 8.0). The 96 result-
ing fractions were then pooled in a noncontinuous manner into 
24 fractions [as outlined in figure S5 of (73)], and 12 fractions (even 
numbers) were used for subsequent MS analysis. Fractions were 
vacuum-centrifuged to near dryness. Each consolidated fraction was 
desalted via StageTip, dried again via vacuum centrifugation, and 
reconstituted in 5% ACN and 1% formic acid for LC–tandem MS 
processing.
MS data were collected using an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA) coupled to a 
Proxeon EASY-nLC1200 LC pump (Thermo Fisher Scientific). 
Peptides were separated on a 100–m–inner diameter micro-
capillary column packed in house with ∼35 cm of Accucore150 resin 
(2.6 m, 150 Å; Thermo Fisher Scientific, San Jose, CA) with a gra-
dient consisting of 5 to 21% (0 to 125 min), 21 to 28% (125 to 140 min) 
(ACN and 0.1% formic acid) over a total 150-min run at ∼500 nl/min. 
For analysis, we loaded one-tenth of each fraction onto the column. 
Each analysis used the Multi-Notch MS3-based TMT method (74) to 
reduce ion interference compared to MS2 quantification (75). The 
scan sequence began with an MS1 spectrum (Orbitrap analysis; 
resolution 120,000 at 200 Th; mass range of 400 to 1400 m/z; AGC 
target, 5 × 105; maximum injection time, 50 ms). Precursors for MS2 
analysis were selected using a Top10 method. MS2 analysis consisted 
of collision-induced dissociation [quadrupole ion trap analysis; Turbo 
scan rate; AGC, 2.0 × 104; isolation window, 0.7 Th; normalized col-
lision energy (NCE) 35; maximum injection time, 90 ms]. Monoisotopic 
peak assignment was used, and previously interrogated precursors 
were excluded using a dynamic window (150 s ± 7 ppm), and de-
pendent scans were performed on a single charge state per precursor. 
Following acquisition of each MS2 spectrum, a synchronous-precursor- 
selection MS3 scan was collected on the top 10 most intense ions in 
the MS2 spectrum (74). MS3 precursors were fragmented by HCD 
and analyzed using the Orbitrap (NCE, 65; AGC, 3 × 105; maximum 
injection time, 150 ms, resolution was 50,000 at 200 Th). A detailed 
protocol describing whole-cell proteomics and TMT-based proteomics 
has been reported (dx.doi.org/10.17504/protocols.io.bxa4pigw).
Immunoprecipitation of diGLY-containing peptides
diGLY capture was performed largely as described (25). The diGLY 
monoclonal antibody (Cell Signaling Technology; D4A7 clone) (32 g 
of antibody/1 mg of peptide) was coupled to Protein A Plus Ultra-
link resin (1:1 l of slurry/g of antibody) (Thermo Fisher Scientific) 
overnight at 4°C before its chemical cross-linking reaction. Dried 
peptides (1-mg starting material) were resuspended in 1.5 ml of ice-
cold immuno affinity purification (IAP) buffer [50 mM Mops 
(pH 7.2), 10 mM sodium phosphate, and 50 mM NaCl] and centrifuged 
at maximum speed for 5 min at 4°C to remove any insoluble mate-
rial. Supernatants (pH  ∼  7.2) were incubated with the antibody 
beads for 2 hours at 4°C with gentle end-over-end rotation. After 
centrifugation at 215g for 2 min, beads were washed three more 
times with ice-cold IAP buffer and twice with ice-cold PBS. The 
diGLY peptides were eluted twice with 0.15% trifluoroacetic acid, 
desalted using homemade StageTips, and dried via vacuum centrifu-
gation, before TMT labeling. A detailed protocol describing the 
diGLY immunoprecipitation for TMT proteomics has been reported 
(dx.doi.org/10.17504/protocols.io.buyunxww).
Proteomics—diGLY proteomic analysis using TMT
The procedure is previously described in https://doi.org/10.1016/j.
molcel.2019.11.013. TMT-labeled diGLY peptides were fractionated 
according to the manufacturer’s instructions using high-pH reversed- 
phase peptide fractionation kit (Thermo Fisher Scientific) for a final six 
fractions and subjected to C18 StageTip desalting before MS analysis.
MS data were collected using an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA) coupled to a 
Proxeon EASY-nLC1200 LC pump (Thermo Fisher Scientific). 
Peptides were separated on a 100–m–inner diameter microcapillary 
column packed in house with ∼35 cm of Accucore150 resin (2.6 m, 
150 Å; Thermo Fisher Scientific, San Jose, CA) with a gradient con-
sisting of 3 to 26% (0 to 130 min) and 26 to 32% (130 to 140 min) 
(ACN and 0.1% formic acid) over a total 150-min run at ∼500 nl/
min. For analysis, we loaded one-half of each fraction onto the column. 
Each analysis used the Multi-Notch MS3-based TMT method (74). 
The scan sequence began with an MS1 spectrum (Orbitrap analysis; 
resolution, 120,000 at 200 Th; mass range, 400 to 1250 m/z; AGC 
target, 1 × 106; maximum injection time, 100 ms). Precursors for 
MS2 analysis were selected using a Top 4 s method. MS2 analysis 
consisted of collision-induced dissociation (quadrupole Orbitrap 
analysis; AGC, 1 × 105; isolation window, 0.7 Th; NCE, 35; maximum 
injection time, 300 ms; resolution was 7500 at 200 Th). Monoisotopic 
peak assignment was used, and previously interrogated precur-
sors were excluded using a dynamic window (120 s ± 7 ppm). As 
described previously, only precursors with a charge state between 3 
and 6 were selected for downstream analysis (25). Following acqui-
sition of each MS2 spectrum, a synchronous-precursor-selection MS3 
scan was collected on the top 10 most intense ions in the MS2 spec-
trum (74). MS3 precursors were fragmented by HCD and analyzed 
using the Orbitrap (NCE, 65; AGC, 2 × 105; maximum injection 
time, 500 ms; resolution was 50,000 at 200 Th). A detailed protocol 
describing the diGLY immunoprecipitation-based TMT proteomics 
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Proteomics—Data analysis
Mass spectra were processed using a SEQUEST-based or Comet- 
based (2014.02 rev. 2) in-house software pipeline (76, 77). Spectra 
were converted to mzXML using a modified version of ReAdW.exe. 
Database searching included all entries from the Mouse Reference 
Proteome (2017-05) UniProt database, as well as an in-house curated 
list of contaminants. This database was concatenated with one com-
posed of all protein sequences in the reversed order. Searches were 
performed using a 20-ppm precursor ion tolerance for total protein 
level analysis. The product ion tolerance was set to 0.9 Da (0.03 Da 
for diGLY searches). These wide mass tolerance windows were chosen 
to maximize sensitivity in conjunction with SEQUEST searches and 
linear discriminant analysis (77, 78). TMT tags on lysine residues 
and peptide N termini (+229.163 Da) and carbamidomethylation of 
cysteine residues (+57.021 Da) were set as static modifications, while 
oxidation of methionine residues (+15.995 Da) was set as a variable 
modification. For phosphorylation dataset search, phosphorylation 
(+79.966 Da) on serine or threonine and deamidation (+0.984 Da) 
on asparagine or glutamine were set as additional variable modifi-
cations. For diGLY dataset search, GlyGly modification (+114.0429 
Da) was also set as a variable modification. PSMs were adjusted to a 
1% FDR (79). PSM filtering was performed using a linear discrimi-
nant analysis, as described previously (77), while considering the 
following parameters: XCorr (or Comet Log Expect), Cn (or Diff 
Seq. Delta Log Expect), missed cleavages, peptide length, charge state, 
and precursor mass accuracy. For TMT-based reporter ion quanti-
tation, we extracted the summed signal-to-noise ratio for each TMT 
channel and found the closest matching centroid to the expected 
mass of the TMT reporter ion (integration tolerance of 0.003 Da). 
For protein-level comparisons, PSMs were identified, quantified, 
and collapsed to a 1% peptide FDR and then collapsed further to a 
final protein-level FDR of 1%. Moreover, protein assembly was guided 
by principles of parsimony to produce the smallest set of proteins 
necessary to account for all observed peptides. Phosphorylation or 
ubiquitylation site localization was determined using the AScore algo-
rithm (78). AScore is a probability-based approach for high-throughput 
protein phosphorylation site localization. Specifically, a threshold 
of 13 corresponded to 95% confidence in site localization. Proteins 
and phosphorylated or ubiquitylated peptides were quantified by 
summing reporter ion counts across all matching PSMs using in-
house software, as described previously (77). PSMs with poor qual-
ity, MS3 spectra with isolation specificity less than 0.7, or with TMT 
reporter summed signal-to-noise ratio that were less than 150, or 
had no MS3 spectra were excluded from quantification (80).
Protein or peptide quantification values were exported for further 
analysis in Microsoft Excel, GraphPad Prism, and Perseus (70). For 
whole-proteome analysis, each reporter ion channel was summed across 
all quantified proteins and normalized assuming equal protein load-
ing of all samples. For diGLY samples, the data were normalized to 
each individual protein abundance measured in parallel when avail-
able to correct for variation in protein abundance between treatments. 
Supplementary tables list all quantified proteins and associated TMT 
reporter ratio to control channels used for quantitative analysis.
Annotations for bona fide organellar protein markers were as-
sembled using the proteins which had scored with confidence “very high” 
or “high” from the HeLa dataset previously published by Itzhak et al. 
(81). The following database containing mitochondrial protein 
was used: MitoCarta 3.0 (34). Detailed protocols describing the 
analysis for diGLY immunoprecipitation and TMT proteomics 
(dx.doi.org/10.17504/protocols.io.buyunxww) and whole-cell TMT 
proteomics (dx.doi.org/10.17504/protocols.io.bxa4pigw) have 
been reported.
Mitochondrial UB and poly-UB capture and proteomics
Mitochondrially derived ubiquitylated proteins were purified using 
Halo-4×UBAUBQLN1 and Halo-5xUBADSK2 as described (15, 82). Briefly, 
whole-cell extracts (0.5 mg) or mitochondrial extracts (0.5 mg) 
that were lysed in lysis buffer containing 50 mM chloroacetamide 
were incubated at 4°C for 16 hours with 25 l of Halo-4×UBAUBQLN1 
beads (pack volume). Subsequently, the supernatant was incubated 
with 15 l of Halo-5xUBADSK2 for 2 hours to capture any possible 
residual mono-ubiquitylated proteins. Halo beads were combined 
and following four washes with lysis buffer containing 0.5 M NaCl 
and one final wash in 10 mM tris (pH 8.0); proteins were released 
from the Halo-UBA resin using 6 M guanidine HCL. Samples were 
subjected to TCA precipitation and digested overnight at 37°C with 
Lys-C and trypsin [in 100 mM tetraethylammonium bromide, 0.1% 
Rapigest (Waters Corporation), 10% (v/v) ACN]. Digests were acid-
ified with an equal volume of 5% (v/v) formic acid to a pH of ∼2 for 
30 min, dried down, resuspended in 5% (v/v) formic acid, and sub-
jected to C18 StageTip (packed with Empore C18; 3 M Corporation) 
desalting. Samples were analyzed by LC/tandem MS for AQUA pro-
teomics as described below. Ubiquitin capture for proteomics was 
performed largely as described previously (15, 82).
UB-AQUA proteomics
UB-AQUA was performed largely as described previously (15, 82). 
A collection of 21 heavy-labeled reference peptides (15, 82), each con-
taining a single 13C/15N-labeled amino acid, was produced at 
Cell Signaling Technologies and quantified by amino acid analysis. 
UB-AQUA peptides from working stocks [in 5% (v/v) formic acid] 
were diluted into the digested sample [in 5% (v/v) formic acid] to be 
analyzed to an optimal final concentration predetermined for indi-
vidual peptide such that each peptide’s intensity would range be-
tween 106 and 108. Samples and AQUA peptides were oxidized with 
0.1% hydrogen peroxide for 30 min, subjected to C18 StageTip, and 
resuspended in 5% (v/v) formic acid. Replicate experiments were 
performed and analyzed sequentially by LC/MS on an Orbitrap Fusion 
Lumos instrument coupled to an Easy-nLC 1200 (Thermo Fisher 
Scientific) ultra-HPLC pump. Peptides were separated on a 100–m– 
inner diameter microcapillary column packed in house with ∼35 cm 
of Accucore150 resin (2.6 m, 150 Å; Thermo Fisher Scientific, San 
Jose, CA). The column was equilibrated with buffer A (3% ACN + 
0.125% formic acid). Peptides were loaded onto the column in 100% 
buffer A. Separation and elution from the column were achieved 
using a 75-min 0 to 28% gradient of buffer B [100% (v/v) ACN + 
0.125% formic acid]. The scan sequence began with FTMS1 spectra 
(resolution of 120,000; mass range, 300 to 1000 m/z; AGC target, 
5 × 105; maximum injection time of 100 ms). The second scan se-
quence consisted of a targeted-MS2 method that was MS2 precur-
sors of interest was isolated using the quadrupole and analyzed in 
the Orbitrap (FTMS2) with a 0.7 Th isolation window, 30,000 reso-
lution, 5 × 104 AGC target, and a maximum injection time of 54 ms. 
MS2 precursors were fragmented by HCD at an NCE of 32%. LC-
MS data analysis was performed using Skyline software (83) with 
manual validation of precursors and fragments. The results 
exported to Excel and GraphPad Prism for further analysis 
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total UB calculated for each individual locus, unless specified 
otherwise.
Proteomics—Ubiquitylated site ranking analysis
In addition to TMT-based reporter ion quantitation, we also extracted 
the MS1 precursor abundance (intensity-based) for each diGLY 
peptide, a value indicative of the relative abundance of the peptide 
in the tryptic sample. Each MS1-based abundance measured should be 
a representation of the sum of all the respective TMT-labeled pep-
tides combined. Therefore, for a rudimentary metric of site abun-
dance across samples, we divided the total MS1 abundance for 
individual diGLY peptides by their respective TMT summed signal-
to-noise ratio to each TMT channel.
Mouse breeding and maintenance
The C57BL/6J mice were obtained from Charles River Laboratories 
(Kent-UK); the PINK1 and Parkin KO mouse models used in this 
study were generated as previously described (29) housed in a spe-
cific pathogen–free facility in temperature-controlled rooms at 
21°C, with 45 to 65% relative humidity and 12-hour light/12-hour 
dark cycles. Mice had ad libitum access to food and water and regu-
larly monitored by the School of Life Science Animal Unit Staff. All 
animal studies and breeding were approved by the University of 
Dundee Ethical Review Committee and further subjected to ap-
proved study plans by the Named Veterinary Surgeon and Compliance 
Officer (N. Dennison). Experiments were conducted in accordance 
with the Animal Scientific Procedures Act (1986) and with the 
Directive 2010/63/EU of the European Parliament and of the 
Council on the protection of animals used for scientific purposes 
(2010, no. 63).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abj0722
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